# Patent

## Title
Mutant MHC class I molecules

## Abstract

This application is a divisional of U.S. application Ser. No. 08/444,185, filed May 18, 1995, which is a continuation of U.S. application Ser. No. 08/180,528, filed Jan. 12, 1994, abandoned, which is a division of U.S. application Ser. No. 07/991,512, filed Dec. 17, 1992, abandoned, which is a continuation of U.S. application Ser. No. 07/661,820, filed Feb. 28, 1991, abandoned.

## Background
This invention refers to the PCTD plasmid isolated from Chlamydia trachomatis serotype D, cloned and sequenced and to the genes present in said plasmid, to the proteins expressed by said genes, to the expression vectors containing said genes and to the microrganisms transformed by said vectors. The invention further refers to the process for the preparation of genes and of said vectors and to the use of said proteins as antigens for the preparation of polyclonal and monoclonal antibodies apt to recognize Chlamydia trachomatis and hence useful for the preparation of vaccines capable of imparting a protective immunity against infections caused by Chlamydia trachomatis and pathologic conditions deriving from said infections and for the development of diagnostic methods for the search of specific antibodies produced following C. trachomatis infections.

Chlamydias are gram-negative bacteria, obligate intracellular parasites of eukariotic cells. Chlamydias show an extracellular infective and metabolically practically inert form, called elemental body (EB), and intracellular replicative forms called reticular bodies (RB).

The reticular bodies, after multiplication by binary fission, are transformed into elemental bodies which come out of the host cell and infect new cells.

The masses or mini-colonies of reticular and elemental bodies inside an infected cell constitute the characteristic "inclusions" visible at the optical microscope.

Chlamydia trachomatis (C. trachomatis or CT), a bacterial species pathogenic to man, is the etiological agent of venereal lymphogranuloma (VLG), of various inflammatory patologies of the genital male and female apparatus and of trachoma, a chronic disease which affects 500 million people and can lead to blindness. In the technical literature ca. 15 CT serotypes pathogenic to man were described and divided in two groups which differ both as to virulence and tissular tropism.

Twelve serotypes of the trachoma group (biovar) are identified as A to K and infect, in general, epithelial tissues, such as the ocular (trachoma) and uro-genital (cervicitis and urethritis) mucous membranes, and show a low virulence.

The venereal lymphogranuloma (VLG) serotypes (L.sub.1, L.sub.2 and L.sub.3) cause instead an infection of the reticulo-endothelial tissue, mainly of the inguinal and femoral lymphonodi, and are highly invasive. Urethritis and cervicitis induced by CT (A to K serotypes) when not precociously diagnosed and treated by adequate therapy, may led to a variety of chronic inflammations, such as, e.g., vaginitis, salpingities and pelvic inflammation which may resolve in sterility and extrauterine pregnancy.

Furthermore the new born from infected mothers may contract pulmonary and/or ocular infections during delivery.

For said reason it is necessary to possess adequate diagnostic methods for determining CT and formulating effective vaccines against said bacterium.

As known, factors which determine the bacterial virulence are often encoded by genes present on plasmids.

In the literature, the presence is reported, in all 15 serotypes and in the clinical isolates examined up to now, of a plasmid of ca. 7.5 Kb referred to in the present invention as pCT followed by the denomination of the bacterial serotype concerned. For example: pCTD for the plasmid isolated from serotype D, etc.

Up to now, however, no specific function or products encoded by it were associated with said plasmid.

A variant of the plasmid, corresponding to serotype D, was now isolated, indicated in what follows a pCTD, which comprises at least eight genes encoding for new proteins.

FIG. 1a shows the nucleotidic sequence of said plasmid and 7 of the 8 protein structures expressed by said sequence. The eighth protein structure, encoded on the DNA chain complemental to the one of FIG. 1a, is shown in FIG. 1b.

Object of the present invention are thus: the cloned and sequenced PCTD plasmid, the nucleotide sequences encoding for the above named proteins, the expression vectors containing one of said sequences or fragments thereof.

Further object of the present invention are the pCTD proteins or fragments of them having immunogenic properties.

Still another object of the present invention are the fusion polypeptides comprising one of said proteins or its fragments suitable as antigens.

The present invention further refers to the preparation of said proteins and of their fragments possessing immunogenic activity or of fused polypeptides comprising said proteins.

Said proteins, their fragments or fusion polypeptides comprising said proteins or their fragments, according to the invention may be employed to determine the CT produced infections in biological samples.

Said proteins, their fragments or fusion polypeptides comprising the protein or its fragments may further be employed, according to the invention, as antigens useful in the formulation of vaccines against infections due to CT.

According to the invention, said proteins, their fragments or fusion polypeptides may be used furthermore as antigens for the preparation of poly- or mono-clonal antibodies to be used in diagnostics.

In particular, the present invention relates to the pgp 3D protein encoded by the gene of the pCTD plasmid identified as ORF3D having the nucleotide sequence reported in FIG. 2, and characterized by a molecular weight of 27,802 and by the aminoacid sequence reported in FIG. 2.

According to the present invention, plasmid pCTD is obtained from the C. trachomatis G0/86 strain isolated from the urethra of a patient with non-gonococcic urethritis, and successively identified as serotype D by the immunofluorescence method described by Wang, S. P. and Grayston, J. T. [Am. J. Ophtalmol. 70; 367-374 (1970)].

The ORF3D gene may be isolated from the PCTD plasmid employing one of the known methods such as, e.g., the in vitro amplification method [Saiki, A. K. et al. Science, 239:487-491 (1988)] using as primers synthetic oligonucleotides having a primary structure suitably derived from the sequence data shown in FIGS. 1a and 1b. The thus emplified gene is then cloned in a vector placing it under the control of sequences regulating its expression.

One can similarly proceed for the other seven genes the nucleotide sequences of which are reported in FIGS. 1a and 1b.

The proteins encoded by said genes are represented by the aminoacid sequences also reported in FIGS. 1a and 1b.

Vectors suitable for the ends of the present invention may be plasmids with expression in host cells selected among the ones known and available commercially or at authorized collection centers. The cells transformed by said vectors are then cultivated in a suitable culture medium in the presence of carbon-, nitrogen- and mineral salts sources, possibly in induction conditions, at a temperature and time period selected in order to obtain the production of the desired protein.

Said protein, obtainable also as fused polypeptide, constituted by a polypeptide produced by the vector fused with the protein itself, is then separated and purified from the culture medium or from the cell lysate.

According to one embodiment of the present invention, the ORF3D gene is cloned in the plasmidic E. coli pEX34a vector, a derivative of pEX29 and pEX31 described by Strebel et al. [J.Virol., 57:983-991 (1986)], following the description by Nicosia et al. in Infect. Imm. 1987, Vol.55, 963-967.

The results show the presence in the bacterial extracts of a polypeptide, indicated as MS2-pgp3D, the sequence of which is shown in FIG. 3, with a mol. weight of ca. 39 Kd, consisting i.e. of a RNA-polymerase fragment of bacteriofage MS2, produced by the expression system of ca. 11 Kd and by the protein encoded by the ORF3D gene of ca. 28 Kd.

Said polypeptide employed as antigen in a Western-Blot assay, or in immunologic assays, is recognized by antibodies present in the serum of patients with CT infection and may further be employed for the production, in laboratory animals, of mono- and poly-clonal antibodies which recognize the - and react with the corresponding pgp3 protein, in all its variants, of C. trachomatis.

In accordance with the present invention the pCTD and p03/60/MCI plasmids were deposited as ATCC N.degree. 68314 and ATCC N.degree. 68315 respectively.

The experimental examples that follow are illustrative and non limitative of the invention.

C. trachomatis cells were isolated following known techniques from the urethra of a patient with non-genococcic urethritis. The strain, identified as serotype D by the micro-immunofluorescence technique described by Wang, S. P. and Grayston, J. T. [(1970), Am. J. Ophtalmol., 70: 367-374] is designated as G0/86.

The elemental bodies of said strain are then purified as described by Cevenini R. et al. [(1988), FEMS Microbiol. Letters, 56:41-46] on renografin.sup.R density discontinuous gradients (E.R. Squibb & Sons, Princeton, N.J.) according to what reported by Caldwell H. D. et al. [(1988) Infect. Immun. 31:1161-1176].

After purification, the elemental bodies (ca. 1.5 mg proteins) are lysated by incubation in 10 mM Tris-HC1, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.6% SDS and 100 mg/ml K Proteinase (Boehringer) at 37.degree. C. for 3 hrs. The total nucleic acids are then extracted with phenol/chloroform, precipitated with ethanol, treated with pancreatic RNAse (250 ng/.mu.l final concentration), further precipitated with ethanol and re-suspended in 800 .mu.l water (365 ng/.mu.l of DNA).

A 10 .mu.l aliquot of said solution is then treated with 30 units (U) of BamHI restriction enzyme (Boehringer) at 37.degree. C. for 2 hrs in 20 .mu.l (final volume) of a digestion mixture suggested by the supplier. 3 .mu.l of the resulting digestion mixture are ligated to 100 ng plasmidic pUC8 DNA previously digested with BamHI and dephosphorilated with calf gut phosphatase. The ligase reaction is effected overnight in 20 .mu.l buffer containing 9 U T4 DNA ligase (Boehringer) at 18.degree. C.

The ligation mixture is then employed to transform HB101 E. coli cells made competent by a treatment with CaCl.sub.2 as described by Mandel and Higa [(1970) J. Mol. Biol: 53, 54]. The transformants are selected on LB agar Medium (DIFCO) with addition of 100 .mu.g/ml ampicillin, at 37.degree. C. overnight.

The positive clones (ampicillin resistant) (Amp.sup.R) containing, that is, the recombinant pUC8 plasmid are transferred onto Hybond-N membranes (Amersham) and sorted by hybridization with three .sup.32 P marked oligonucleotides having the following nucleotidic sequences:

The above reported oligonucleotides are synthesized by means of an automatic synthesizer (Applied Biosystem Inc. Mod. 380A) following the methods and employing the reagents recommended by the manufacturers.

Four of the six plasmids isolated from the clones found positive at the hybridization, analyzed by electrophoresis on agarose 1% gel before and after digestion with BamHI are found to consist of the pUC8 plasmid nucleotidic sequence and of a nucleotidic insert of ca. 7.5 kilobases corresponding to the isolated C.trachomatis G0/86 plasmid.

The nucleotidic sequences of said insert is determined according to the method of Sanger F. [(1977) PNAS USA 74:5463-5467] utilizing a series of suitable primers. The sequencing reactions are performed on double helix DNA employing the Sequenase Kit (U.S. Biochemical Co. Cleveland, Ohio) as recommended by the firm.

The nucleotidic sequences of the ca. 7.5 kilobases plasmid named pCTD are reported in FIGS. 1a and 1b. The recombinant plasmid containing said insert is indicated as pUC8-pCTD.

The DNA fragment denoted as ORF3D(FIG. 2) of 792 bp is obtained through in vitro amplification according to the technique known as Polymerase Chain Reaction (PCR) described by Saiki A. K. et al. [(1988) Science 239:487-491].

The amplification is effected utilizing ca. 10 ng of the pUC8-pCTD plasmid and employing as primers two synthetic oligonucleotides (ORF31) and (ORF3dx) having respectively the following nucleotide sequences (SEQ ID NO:4 and SEQ ID NO:5): BamHI -5'CCCCTGCAGTTAAGCGTTTGTTTGAGGT3' Pst I

Said oligonucleotides are complemental to ORF3 regions with the addition to the respective 5' terminals of a nucleotide sequence comprising the action site of a restriction enzyme selected among the ones present in the pEX34A vector (Strebel K. et al. [(1986, J. Virol.57: 983-991] utilized for the successive cloning. In particular, the site selected for ORF31 is the one for the BamHI enzyme, while for ORF3dx is the one of the PstI enzyme.

The amplification reaction is performed employing the reagents contained in the "Geneamp" Kit (Perkin Elmer-Cetus). 25 amplification cycles are effected. Each amplification cycle consists in heating the reaction mixture to 94.degree. C. for one minute, to 50.degree. C. for one minute and finally to 72.degree. C. for one minute.

At the end of the amplification reaction the mixture is extracted, in succession, with an equal volume of phenol and of a chloroform-isoamyl alcohol mixture (24:1 v/v) and then submitted to forced dialysis by means of Centricon cartridges following the producer's (Amicon) instructions.

The DNA is then precipitated by adding to the obtained solution sodium acetate 3 M, pH 5.5 (1/10 of the volume) and cold (-20.degree. C.) ethanol (3 vols.). The DNA precipitate is dissolved in 44 .mu.l water. To the solution, 5 .mu.l H buffer (Boehringer) and 1 .mu.l PSTI restriction enzyme (20 units/.mu.l) are added and the DNA is digested at 37.degree. C. for 2 hours.

The digestion mixture is then extracted with phenol, chloroform/isoamyl alcohol and then the DNA is precipitated with ethanol (-20.degree. C.). The precipitate, separated by centrifugation, is suspended again in 44 .mu.l water and then digested with 20 U BamHl in 5 .mu.l of B buffer (Boehringer) at 37.degree. C. for 2 hours. The digestion mixture is extracted with phenol, chloroform/isoamyl alcohol and dialyzed by Centricon.sup.R cartridge.

At the same time, 10 .mu.g of the pEX34A plasmidic vector are digested with the PstI and BamHI restriction enzymes as reported supra. The vector is dephosphorylated with alkaline phosphatase, extracted with phenol and chloroform/isoamyl alcohol, precipitated with ethanol (-20.degree. C.) and re-suspended in 50 .mu.l water.

1 .mu.l (100 ng) of the vector and 2 .mu.l (200 ng) of the amplified ORF3D segment are then ligated in 2 .mu.l ligase buffer to which 2 .mu.l ATP r, 1 .mu.l T4 DNA ligase (9 units/.mu.l) are added, adding water to a total volume of 20 .mu.l. The ligase reaction is performed at 15.degree. C. overnight. The ligase mixture is employed to transform 200 .mu.l of a suspension of E. coli competent cells (K12-.DELTA.H1-.DELTA.trp) [Remaut E. et al. (1983), Gene 22:103-113]. After treatment at 30.degree. C. for 5 minutes, to the cell suspension 800 .mu.l LB medium are added, followed by incubation at 30.degree. C. for 1 hour. Aliquots of the cell suspension (10 .mu.l, 100 .mu.l and 690 .mu.l) are separately plated on plates of agarized (20 g/l) LB medium containing 100 .mu.g/mg ampicillin and kept at 30.degree. C. overnight.

The obtained clones (Amp.sup.R) are transferred to a nitrocellulose membrane on a LB agar plate with added ampicillin, grown at 30.degree. C. overnight, and then tested for hydridization with three oligonucleotidic probes (UB35, UB36, UB18) terminally marked with .sup.32 P having the following sequences:

The hybridization test is performed according to known tecnique. From the colonies positive to hybridization the plasmids contained in them are prepared by minipreparation as described by Maniatis et al. (1982) and the ORF3D insert nucleotide sequence is controlled by known technique.

E. coli cells containing the pEX34 vector with the ORF3D insert are inoculated in duplicate in 10 ml LB medium with added 30 .mu.g/ml ampicillin and cultivated at 30.degree. C. overnight. The procedure described by Nicosia et al. [Inf. Imm. (1987) 55:963-967] is then followed, with the provision that one of two duplicates undergoes induction of the cloned gene by treatment at 42.degree. C., while the other does not. Two protein extracts are thus obtained, produced by the bacterium, in 7M urea buffered at pH 8, one of which corresponds to the induced cells, and the other, as a control, to the non-induced cells. By analysis of the protein contents of both extracts by electrophoresis in SDS-polyacrylamide 15% gel according to known techniques, it is possible to deduct the presence of a protein species of 39,000 apparent mol.wt. which is present in a considerably greater amount in the induced extracts.

In the non-induced cell lysate no evidence of such a protein, but only the product of the vector alone, is found.

Said electrophoresis patterns may be analyzed by the Western Blot technique employing a monoclonal antibody (SCLAV0) specific for the 11 kd fragment generated by the pEX34 vector. In this way it is possible to demonstrate that the 39 kd band is a fusion protein containing said fragment.

The protein extract, from induced bacterial cells, re-suspended in 7M urea, is dialyzed for 15 hrs. at 4.degree. C. against a PBS buffer consisting of 0.4% KCl, 0.4% KH.sub.2 PO.sub.4, 16% NaCl, 2.5% NaH.sub.2 PO.sub.4.

During the dialysis a protein precipitate is obtained, which is separated by centrifuging and discarded. The surnatant is submitted to further purification by electrophoresis on preparative 12.5% acrylamide gels, and the protein band of 39,000 mol.wt. (MS2-pgp3D) is then extracted by electroelution from the gel.

The thus obtained MS2-pgp3 is precipitated by adding to the electroeluted solution 9 volumes of absolute acetone (-20.degree. C.). The protein precipitate is separated by centrifuging, re-suspended in 90% acetone, centrifuged as above, precipitated in 96% acetone and centrifuged again. The precipitate is brought to dryness in a nitrogen stream and re-suspended in 200 .mu.l sterile PBS at a final concentration of approximately 1.5 .mu.g/pl.

The advantage of the effected dialysis is the elimination, with this procedure, of some E. coli proteins, in particular some with a molecular weight equal or very near to the one of the desired recombinant product, which may present a considerable hinderance in the electrophoretic and/or chromatographic purification.

Utilizing the MS2-pgp3 protein, purified as in Example 4, 3 Balb/C 7-8 week old mice are immunized intraperitoneally. The immunization procedure comprises a first injection of 0.2 ml/mouse of an emulsion consisting of one part by vol. of the purified protein solution (1.5 .mu.g/uml) and five parts of Freund complete adjuvant (FCA).

The thus inoculated protein amount is thus ca. 50 .mu.g/mouse.

After 1 week the mice are immunized with the said same emulsion, followed by a 800 .mu.l Pristane injection. After 1 week from the second inoculation, the mice are intraperitoneally immunized with 0.2 ml of a solution similar to the first one. Finally, after two weeks from the third inoculation a booster immunization is effected.

The thus induced antibodies are collected in the ascitic fluid formed after the above described treatment.

The anti MS2-pgp3 antibody titres show values comprised between 1:8000 and 1:10.000 evaluated by analysis with Western Blot containing the MS2-pgp3 protein.

The reactivity of said antibodies to the native antigen (pgp3) was evaluated according to the following methods: purified CT bodies;

The results of the above tests show that the anti MS2-pgp3 antibodies are able to reveal C. trachomatis inclusions in infected cells (see immunofluorescence test) and recognize a protein present in the bacterium protein extracts and having a mol.wt. of 28 kd, equivalent, that is, to the one of the protein encoded by ORF3D (see Western Blot test).

To the end of preparing monoclonal anti-MS2-pgp3 antibodies, the mice, immunized as above described, are sacrificed, the spleens extracted and utilized for the preparation of hybridomas operating according to the technique described by Davis L. G. [Basic methods in molecular biology--Elsevier Edit., New York (1986)]. The screening of the thus obtained hybridomas is performed as described for the polyclonal antibodies. In particular, a screening was performed with induced E. coli extracts (see Example 3) containing the MS2-pgp3 protein or the polypeptide encoded by the pEX34 vector alone; obviously, the clones were selected which produced antibodies reacting only with the recombinant product. With such pgp3-specific antibodies, results are obtained which are superimposable to the ones obtained with the above described polyclonal antibodies.

Serum samples from 20 patients with Chlamydia generated infections were collected. Said sera contained anti-Chlamydia antibodies with titres comprised between 128 and 512, as determined by immunofluorescence against single antigen (LGV2). 15 control sera not containing anti-Chlamydia antibodies were obtained from healty donors. Western Blots were prepared, as above described, containing the MS2-pgp3 protein. These were incubated with the sera under examination diluted 1:100 and successively with peroxidase marked rabbit (anti human IgG) immunoglobines. 16 of the 20 infected patients sera contained antibodies apt to react with MS2-pgp3. The 15 healthy control sera did not give any reaction with said protein. (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 23 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 ATGGGTAAAG GGATTTTATC                                                 20 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 CTATATTAGA GCCATCTTC                                                  19 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 TCAAAGCGCT TGCACGAAG                                                  19 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 CAGGGATCCA TGGGAAATTC TGGTTTTT                                        28 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 CCCCTGCAGT TAAGCGTTTG TTTGAGGT                                        28 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7502 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 ATATTCATAT TCTGTTGCCA GAAAAAACAC CTTTAGGCTA TATTAGAGCC ATCTTCTTTG     60 AAGCGTTGTC TTCTCGAGAA GATTTATCGT ACGCAAATAT CATCTTTGCG GTTGCGTGTC    120 CTGTGACCTT CATTATGTCG GAGTCTGAGC ACCCTAGGCG TTTGTACTCC GTCACAGCGG    180 TTGCTCGAAG CACGTGCGGG GTTATTTTAA AAGGGATTGC AGCTTGTAGT CCTGCTTGAG    240 AGAACGTGCG GGCGATTTGC CTTAACCCCA CCATTTTTCC GGAGCGAGTT ACGAAGACAA    300 AACCTCTTCG TTGACCGATG TACTCTTGTA GAAAGTGCAT AAACTTCTGA GGATAAGTTA    360 TAATAATCCT CTTTTCTGTC TGACGGTTCT TAAGCTGGGA GAAAGAAATG GTAGCTTGTT    420 GGAAACAAAT CTGACTAATC TCCAAGCTTA AGACTTCAGA GGAGCGTTTA CCTCCTTGGA    480 GCATTGTCTG GGCGATCAAC CAATCCCGGG CATTGATTTT TTTTAGCTCT TTTAGGAAGG    540 ATGCTGTTTG CAAACTGTTC ATCGCATCCG TTTTTACTAT TTCCCTGGTT TTAAAAAATG    600 TTCGACTATT TTCTTGTTTA GAAGGTTGCG CTATAGCGAC TATTCCTTGA GTCATCCTGT    660 TTAGGAATCT TGTTAAGGAA ATATAGCTTG CTGCTCGAAC TTGTTTAGTA CCTTCGGTCC    720 AAGAAGTCTT GGCAGAGGAA ACTTTTTTAA TCGCATCTAG GATTAGATTA TGATTTAAAA    780 GGGAAAACTC TTGCAGATTC ATATCCAAGG ACAATAGACC AATCTTTTCT AAAGACAAAA    840 AAGATCCTCG ATATGATCTA CAAGTATGTT TGTTGAGTGA TGCGGTCCAA TGCATAATAA    900 CTTCGAATAA GGAGAAGCTT TTCATGCGTT TCCAATAGGA TTCTTGGCGA ATTTTTAAAA    960 CTTCCTGATA AGACTTTTCA CTATATTCTA ACGACATTTC TTGCTGCAAA GATAAAATCC   1020 CTTTACCCAT GAAATCCCTC GTGATATAAC CTATCCGTAA AATGTCCTGA TTAGTGAAAT   1080 AATCAGGTTG TTAACAGGAT AGCACGCTCG GTATTTTTTT ATATAAACAT GAAAACTCGT   1140 TCCGAAATAG AAAATCGCAT GCAAGATATC GAGTATGCGT TGTTAGGTAA AGCTCTGATA   1200 TTTGAAGACT CTACTGAGTA TATTCTGAGG CAGCTTGCTA ATTATGAGTT TAAGTGTTCT   1260 CATCATAAAA ACATATTCAT AGTATTTAAA CACTTAAAAG ACAATGGATT ACCTATAACT   1320 GTAGACTCGG CTTGGGAAGA GCTTTTGCGG CGTCGTATCA AAGATATGGA CAAATCGTAT   1380 CTCGGGTTAA TGTTGCATGA TGCTTTATCA AATGACAAGC TTAGATCCGT TTCTCATACG   1440 GTTTTCCTCG ATGATTTGAG CGTGTGTAGC GCTGAAGAAA ATTTGAGTAA TTTCATTTTC   1500 CGCTCGTTTA ATGAGTACAA TGAAAATCCA TTGCGTAGAT CTCCGTTTCT ATTGCTTGAG   1560 CGTATAAAGG GAAGGCTTGA TAGTGCTATA GCAAAGACTT TTTCTATTCG CAGCGCTAGA   1620 GGCCGGTCTA TTTATGATAT ATTCTCACAG TCAGAAATTG GAGTGCTGGC TCGTATAAAA   1680 AAAAGACGAG TAGCGTTCTC TGAGAATCAA AATTCTTTCT TTGATGGCTT CCCAACAGGA   1740 TACAAGGATA TTGATGATAA AGGAGTTATC TTAGCTAAAG GTAATTTCGT GATTATAGCA   1800 GCTAGACCAT CTATAGGGAA AACAGCTTTA GCTATAGACA TGGCGATAAA TCTTGCGGTT   1860 ACTCAACAGC GTAGAGTTGG TTTCCTATCT CTAGAAATGA GCGCAGGTCA AATTGTTGAG   1920 CGGATTATTG CTAATTTAAC AGGAATATCT GGTGAAAAAT TACAAAGAGG GGATCTCTCT   1980 AAAGAAGAAT TATTCCGAGT AGAAGAAGCT GGAGAAACGG TTAGAGAATC ACATTTTTAT   2040 ATCTGCAGTG ATAGTCAGTA TAAGCTTAAC TTAATCGCGA ATCAGATCCG GTTGCTGAGA   2100 AAAGAAGATC GAGTAGACGT AATATTTATC GATTACTTGC AGTTGATCAA CTCATCGGTT   2160 GGAGAAAATC GTCAAAATGA AATAGCAGAT ATATCTAGAA CCTTAAGAGG TTTAGCCTCA   2220 GAGCTAAACA TTCCTATAGT TTGTTTATCC CAACTATCTA GAAAAGTTGA GGATAGAGCA   2280 AATAAAGTTC CCATGCTTTC AGATTTGCGA GACAGCGGTC AAATAGAGCA AGACGCAGAT   2340 GTGATTTTGT TTATCAATAG GAAGGAATCG TCTTCTAATT GTGAGATAAC TGTTGGGAAA   2400 AATAGACATG GATCGGTTTT CTCTTCGGTA TTACATTTCG ATCCAAAAAT TAGTAAATTC   2460 TCCGCTATTA AAAAAGTATG GTAAATTATA GTAACTGCCA CTTCATCAAA AGTCCTATCC   2520 ACCTTGAAAA TCAGAAGTTT GGAAGAAGAC CTGGTCAATC TATTAAGATA TCTCCCAAAT   2580 TGGCTCAAAA TGGGATGGTA GAAGTTATAG GTCTTGATTT TCTTTCATCT CATTACCATG   2640 CATTAGCAGC TATCCAAAGA TTACTGACCG CAACGAATTA CAAGGGGAAC ACAAAAGGGG   2700 TTGTTTTATC CAGAGAATCA AATAGTTTTC AATTTGAAGG ATGGATACCA AGAATCCGTT   2760 TTACAAAAAC TGAATTCTTA GAGGCTTATG GAGTTAAGCG GTATAAAACA TCCAGAAATA   2820 AGTATGAGTT TAGTGGAAAA GAAGCTGAAA CTGCTTTAGA AGCCTTATAC CATTTAGGAC   2880 ATCAACCGTT TTTAATAGTG GCAACTAGAA CTCGATGGAC TAATGGAACA CAAATAGTAG   2940 ACCGTTACCA AACTCTTTCT CCGATCATTA GGATTTACGA AGGATGGGAA GGTTTAACTG   3000 ACGAAGAAAA TATAGATATA GACTTAACAC CTTTTAATTC ACCACCTACA CGGAAACATA   3060 AAGGGTTCGT TGTAGAGCCA TGTCCTATCT TGGTAGATCA AATAGAATCC TACTTTGTAA   3120 TCAAGCCTGC AAATGTATAC CAAGAAATAA AAATGCGTTT CCCAAATGCA TCAAAGTATG   3180 CTTACACATT TATCGACTGG GTGATTACAG CAGCTGCGAA AAAGAGACGA AAATTAACTA   3240 AGGATAATTC TTGGCCAGAA AACTTGTTAT TAAACGTTAA CGTTAAAAGT CTTGCATATA   3300 TTTTAAGGAT GAATCGGTAC ATCTGTACAA GGAACTGGAA AAAAATCGAG TTAGCTATCG   3360 ATAAATGTAT AGAAATCGCC ATTCAGCTTG GCTGGTTATC TAGAAGAAAA CGCATTGAAT   3420 TTCTGGATTC TTCTAAACTC TCTAAAAAAG AAATTCTATA TCTAAATAAA GAGCGCTTTG   3480 AAGAAATAAC TAAGAAATCT AAAGAACAAA TGGAACAATT AGAACAAGAA TCTATTAATT   3540 AATAGCAAGC TTGAAACTAA AAACCTAATT TATTTAAAGC TCAAAATAAA AAAGAGTTTT   3600 AAAATGGGAA ATTCTGGTTT TTATTTGTAT AACACTGAAA ACTGCGTCTT TGCTGATAAT   3660 ATCAAAGTTG GGCAAATGAC AGAGCCGCTC AAGGACCAGC AAATAATCCT TGGGACAACA   3720 TCAACACCTG TCGCAGCCAA AATGACAGCT TCTGATGGAA TATCTTTAAC AGTCTCCAAT   3780 AATTCATCAA CCAATGCTTC TATTACAATT GGTTTGGATG CGGAAAAAGC TTACCAGCTT   3840 ATTCTAGAAA AGTTGGGAGA TCAAATTCTT GATGGAATTG CTGATACTAT TGTTGATAGT   3900 ACAGTCCAAG ATATTTTAGA CAAAATCAAA ACAGACCCTT CTCTAGGTTT GTTGAAAGCT   3960 TTTAACAACT TTCCAATCAC TAATAAAATT CAATGCAACG GGTTATTCAC TCCCAGTAAC   4020 ATTGAAACTT TATTAGGAGG AACTGAAATA GGAAAATTCA CAGTCACACC CAAAAGCTCT   4080 GGGAGCATGT TCTTAGTCTC AGCAGATATT ATTGCATCAA GAATGGAAGG CGGCGTTGTT   4140 CTAGCTTTGG TACGAGAAGG TGATTCTAAG CCCTGCGCGA TTAGTTATGG ATACTCATCA   4200 GGCATTCCTA ATTTATGTAG TCTAAGAACC AGTATTACTA ATACAGGATT GACTCCGACA   4260 ACGTATTCAT TACGTGTAGG CGGTTTAGAA AGCGGTGTGG TATGGGTTAA TGCCCTTTCT   4320 AATGGCAATG ATATTTTAGG AATAACAAAT ACTTCTAATG TATCTTTTTT AGAGGTAATA   4380 CCTCAAACAA ACGCTTAAAC AATTTTTATT GGATTTTTCT TATAGGTTTT ATATTTAGAG   4440 AAAACAGTTC GAATTACGGG GTTTGTTATG CAAAATAAAA GAAAAGTGAG GGACGATTTT   4500 ATTAAAATTG TTAAAGATGT GAAAAAAGAT TTCCCCGAAT TAGACCTAAA AATACGAGTA   4560 AACAAGGAAA AAGTAACTTT CTTAAATTCT CCCTTAGAAC TCTACCATAA AAGTGTCTCA   4620 CTAATTCTAG GACTGCTTCA ACAAATAGAA AACTCTTTAG GATTATTCCC AGACTCTCCT   4680 GTTCTTGAAA AATTAGAGGA TAACAGTTTA AAGCTAAAAA AGGCTTTGAT TATGCTTATC   4740 TTGTCTAGAA AAGACATGTT TTCCAAGGCT GAATAGACAA CTTACTCTAA CGTTGGAGTT   4800 GATTTGCACA CCTTAGTTTT TTGCTCTTTT AAGGGAGGAA CTGGAAAAAC AACACTTTCT   4860 CTAAACGTGG GATGCAACTT GGCCCAATTT TTAGGGAAAA AAGTGTTACT TGCTGACCTA   4920 GACCCGCAAT CCAATTTATC TTCTGGATTG GGGGCTAGTG TCAGAAGTGA CCAAAAAGGC   4980 TTGCACGACA TAGTATACAC ATCAAACGAT TTAAAATCAA TCATTTGCGA AACAAAAAAA   5040 GATAGTGTGG ACCTAATTCC TGCATCATTT TCATCCGAAC AGTTTAGAGA ATTGGATATT   5100 CATAGAGGAC CTAGTAACAA CTTAAAGTTA TTTCTGAATG AGTACTGCGC TCCTTTTTAT   5160 GACATCTGCA TAATAGACAC TCCACCTAGC CTAGGAGGGT TAACGAAAGA AGCTTTTGTT   5220 GCAGGAGACA AATTAATTGC TTGTTTAACT CCAGAACCTT TTTCTATTCT AGGGTTACAA   5280 AAGATACGTG AATTCTTAAG TTCGGTCGGA AAACCTGAAG AAGAACACAT TCTTGGAATA   5340 GCTTTGTCTT TTTGGGATGA TCGTAACTCG ACTAACCAAA TGTATATAGA CATTATCGAG   5400 TCTATTTACA AAAACAAGCT TTTTTCAACA AAAATTCGTC GAGATATTTC TCTCAGCCGT   5460 TCTCTTCTTA AAGAAGATTC TGTAGCTAAT GTCTATCCAA ATTCTAGGGC CGCAGAAGAT   5520 ATTCTGAAGT TAACGCATGA AATAGCAAAT ATTTTGCATA TCGAATATGA ACGAGATTAC   5580 TCTCAGAGGA CAACGTGAAC AAACTAAAAA AAGAAGCGGA TGTCTTTTTT AAAAAAAATC   5640 AAACTGCCGC TTCTCTAGAT TTTAAGAAGA CGCTTCCCTC CATTGAACTA TTCTCAGCAA   5700 CTTTGAATTC TGAGGAAAGT CAGAGTTTGG ATCGATTATT TTTATCAGAG TCCCAAAACT   5760 ATTCGGATGA AGAATTTTAT CAAGAAGACA TCCTAGCGGT AAAACTGCTT ACTGGTCAGA   5820 TAAAATCCAT ACAGAAGCAA CACGTACTTC TTTTAGGAGA AAAAATCTAT AATGCTAGAA   5880 AAATCCTGAG TAAGGATCAC TTCTCCTCAA CAACTTTTTC ATCTTGGATA GAGTTAGTTT   5940 TTAGAACTAA GTCTTCTGCT TACAATGCTC TTGCATATTA CGAGCTTTTT ATAAACCTCC   6000 CCAACCAAAC TCTACAAAAA GAGTTTCAAT CGATCCCCTA TAAATCCGCA TATATTTTGG   6060 CCGCTAGAAA AGGCGATTTA AAAACCAAGG TCGATGTGAT AGGGAAAGTA TGTGGAATGT   6120 CGAACTCATC GGCGATAAGG GTGTTGGATC AATTTCTTCC TTCATCTAGA AACAAAGACG   6180 TTAGAGAAAC GATAGATAAG TCTGATTCAG AGAAGAATCG CCAATTATCT GATTTCTTAA   6240 TAGAGATACT TCGCATCATG TGTTCCGGAG TTTCTTTGTC CTCCTATAAC GAAAATCTTC   6300 TACAACAGCT TTTTGAACTT TTTAAGCAAA AGAGCTGATC CTCCGTCAGC TCATATATAT   6360 ATATCTATTA TATATATATA TTTAGGGATT TGATTTCACG AGAGAGATTT GCAACTCTTG   6420 GTGGTAGACT TTGCAACTCT TGGTGGTAGA CTTTGCAACT CTTGGTGGTA GACTTTGCAA   6480 CTCTTGGTGG TAGACTTGGT CATAATGGAC TTTTGTTAAA AAATTTATTA AAATCTTAGA   6540 GCTCCGATTT TGAATAGCTT TGGTTAAGAA AATGGGCTCG ATGGCTTTCC ATAAAAGTAG   6600 ATTGTTTTTA ACTTTTGGGG ACGCGTCGGA AATTTGGTTA TCTACTTTAT CTTATCTAAC   6660 TAGAAAAAAT TATGCGTCTG GGATTAACTT TCTTGTTTCT TTAGAGATTC TGGATTTATC   6720 GGAAACCTTG ATAAAGGCTA TTTCTCTTGA CCACAGCGAA TCTTTGTTTA AAATCAAGTC   6780 TCTAGATGTT TTTAATGGAA AAGTTGTTTC AGAGGCATCT AAACAGGCTA GAGCGGCATG   6840 CTACATATCT TTCACAAAGT TTTTGTATAG ATTGACCAAG GGATATATTA AACCCGCTAT   6900 TCCATTGAAA GATTTTGGAA ACACTACATT TTTTAAAATC CGAGACAAAA TCAAAACAGA   6960 ATCGATTTCT AAGCAGGAAT GGACAGTTTT TTTTGAAGCG CTCCGGATAG TGAATTATAG   7020 AGACTATTTA ATCGGTAAAT TGATTGTACA AGGGATCCGT AAGTTAGACG AAATTTTGTC   7080 TTTGCGCACA GACGATCTAT TTTTTGCATC CAATCAGATT TCCTTTCGCA TTAAAAAAAG   7140 ACAGAATAAA GAAACCAAAA TTCTAATCAC ATTTCCTATC AGCTTAATGG AAGAGTTGCA   7200 AAAATACACT TGTGGGAGAA ATGGGAGAGT ATTTGTTTCT AAAATAGGGA TTCCTGTAAC   7260 AACAAGTCAG GTTGCGCATA ATTTTAGGCT TGCAGAGTTC CATAGTGCTA TGAAAATAAA   7320 AATTACTCCC AGAGTACTTC GTGCAAGCGC TTTGATTCAT TTAAAGCAAA TAGGATTAAA   7380 AGATGAGGAA ATCATGCGTA TTTCCTGTCT TTCATCGAGA CAAAGTGTGT GTTCTTATTG   7440 TTCTGGGGAA GAGGTAATTC CTCTAGTACA AACACCCACA ATATTGTGAT ATAATTAAAA   7500 TT                                                                  7502 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1356 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..1353 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7 ATG AAA ACT CGT TCC GAA ATA GAA AAT CGC ATG CAA GAT ATC GAG TAT       48 Met Lys Thr Arg Ser Glu Ile Glu Asn Arg Met Gln Asp Ile Glu Tyr 1               5                  10                  15 GCG TTG TTA GGT AAA GCT CTG ATA TTT GAA GAC TCT ACT GAG TAT ATT       96 Ala Leu Leu Gly Lys Ala Leu Ile Phe Glu Asp Ser Thr Glu Tyr Ile 20                  25                  30 CTG AGG CAG CTT GCT AAT TAT GAG TTT AAG TGT TCT CAT CAT AAA AAC      144 Leu Arg Gln Leu Ala Asn Tyr Glu Phe Lys Cys Ser His His Lys Asn 35                  40                  45 ATA TTC ATA GTA TTT AAA CAC TTA AAA GAC AAT GGA TTA CCT ATA ACT      192 Ile Phe Ile Val Phe Lys His Leu Lys Asp Asn Gly Leu Pro Ile Thr 50                  55                  60 GTA GAC TCG GCT TGG GAA GAG CTT TTG CGG CGT CGT ATC AAA GAT ATG      240 Val Asp Ser Ala Trp Glu Glu Leu Leu Arg Arg Arg Ile Lys Asp Met 65                  70                  75                  80 GAC AAA TCG TAT CTC GGG TTA ATG TTG CAT GAT GCT TTA TCA AAT GAC      288 Asp Lys Ser Tyr Leu Gly Leu Met Leu His Asp Ala Leu Ser Asn Asp 85                  90                  95 AAG CTT AGA TCC GTT TCT CAT ACG GTT TTC CTC GAT GAT TTG AGC GTG      336 Lys Leu Arg Ser Val Ser His Thr Val Phe Leu Asp Asp Leu Ser Val 100                 105                 110 TGT AGC GCT GAA GAA AAT TTG AGT AAT TTC ATT TTC CGC TCG TTT AAT      384 Cys Ser Ala Glu Glu Asn Leu Ser Asn Phe Ile Phe Arg Ser Phe Asn 115                 120                 125 GAG TAC AAT GAA AAT CCA TTG CGT AGA TCT CCG TTT CTA TTG CTT GAG      432 Glu Tyr Asn Glu Asn Pro Leu Arg Arg Ser Pro Phe Leu Leu Leu Glu 130                 135                 140 CGT ATA AAG GGA AGG CTT GAT AGT GCT ATA GCA AAG ACT TTT TCT ATT      480 Arg Ile Lys Gly Arg Leu Asp Ser Ala Ile Ala Lys Thr Phe Ser Ile 145                 150                 155                 160 CGC AGC GCT AGA GGC CGG TCT ATT TAT GAT ATA TTC TCA CAG TCA GAA      528 Arg Ser Ala Arg Gly Arg Ser Ile Tyr Asp Ile Phe Ser Gln Ser Glu 165                 170                 175 ATT GGA GTG CTG GCT CGT ATA AAA AAA AGA CGA GTA GCG TTC TCT GAG      576 Ile Gly Val Leu Ala Arg Ile Lys Lys Arg Arg Val Ala Phe Ser Glu 180                 185                 190 AAT CAA AAT TCT TTC TTT GAT GGC TTC CCA ACA GGA TAC AAG GAT ATT      624 Asn Gln Asn Ser Phe Phe Asp Gly Phe Pro Thr Gly Tyr Lys Asp Ile 195                 200                 205 GAT GAT AAA GGA GTT ATC TTA GCT AAA GGT AAT TTC GTG ATT ATA GCA      672 Asp Asp Lys Gly Val Ile Leu Ala Lys Gly Asn Phe Val Ile Ile Ala 210                 215                 220 GCT AGA CCA TCT ATA GGG AAA ACA GCT TTA GCT ATA GAC ATG GCG ATA      720 Ala Arg Pro Ser Ile Gly Lys Thr Ala Leu Ala Ile Asp Met Ala Ile 225                 230                 235                 240 AAT CTT GCG GTT ACT CAA CAG CGT AGA GTT GGT TTC CTA TCT CTA GAA      768 Asn Leu Ala Val Thr Gln Gln Arg Arg Val Gly Phe Leu Ser Leu Glu 245                 250                 255 ATG AGC GCA GGT CAA ATT GTT GAG CGG ATT ATT GCT AAT TTA ACA GGA      816 Met Ser Ala Gly Gln Ile Val Glu Arg Ile Ile Ala Asn Leu Thr Gly 260                 265                 270 ATA TCT GGT GAA AAA TTA CAA AGA GGG GAT CTC TCT AAA GAA GAA TTA      864 Ile Ser Gly Glu Lys Leu Gln Arg Gly Asp Leu Ser Lys Glu Glu Leu 275                 280                 285 TTC CGA GTA GAA GAA GCT GGA GAA ACG GTT AGA GAA TCA CAT TTT TAT      912 Phe Arg Val Glu Glu Ala Gly Glu Thr Val Arg Glu Ser His Phe Tyr 290                 295                 300 ATC TGC AGT GAT AGT CAG TAT AAG CTT AAC TTA ATC GCG AAT CAG ATC      960 Ile Cys Ser Asp Ser Gln Tyr Lys Leu Asn Leu Ile Ala Asn Gln Ile 305                 310                 315                 320 CGG TTG CTG AGA AAA GAA GAT CGA GTA GAC GTA ATA TTT ATC GAT TAC     1008 Arg Leu Leu Arg Lys Glu Asp Arg Val Asp Val Ile Phe Ile Asp Tyr 325                 330                 335 TTG CAG TTG ATC AAC TCA TCG GTT GGA GAA AAT CGT CAA AAT GAA ATA     1056 Leu Gln Leu Ile Asn Ser Ser Val Gly Glu Asn Arg Gln Asn Glu Ile 340                 345                 350 GCA GAT ATA TCT AGA ACC TTA AGA GGT TTA GCC TCA GAG CTA AAC ATT     1104 Ala Asp Ile Ser Arg Thr Leu Arg Gly Leu Ala Ser Glu Leu Asn Ile 355                 360                 365 CCT ATA GTT TGT TTA TCC CAA CTA TCT AGA AAA GTT GAG GAT AGA GCA     1152 Pro Ile Val Cys Leu Ser Gln Leu Ser Arg Lys Val Glu Asp Arg Ala 370                 375                 380 AAT AAA GTT CCC ATG CTT TCA GAT TTG CGA GAC AGC GGT CAA ATA GAG     1200 Asn Lys Val Pro Met Leu Ser Asp Leu Arg Asp Ser Gly Gln Ile Glu 385                 390                 395                 400 CAA GAC GCA GAT GTG ATT TTG TTT ATC AAT AGG AAG GAA TCG TCT TCT     1248 Gln Asp Ala Asp Val Ile Leu Phe Ile Asn Arg Lys Glu Ser Ser Ser 405                 410                 415 AAT TGT GAG ATA ACT GTT GGG AAA AAT AGA CAT GGA TCG GTT TTC TCT     1296 Asn Cys Glu Ile Thr Val Gly Lys Asn Arg His Gly Ser Val Phe Ser 420                 425                 430 TCG GTA TTA CAT TTC GAT CCA AAA ATT AGT AAA TTC TCC GCT ATT AAA     1344 Ser Val Leu His Phe Asp Pro Lys Ile Ser Lys Phe Ser Ala Ile Lys 435                 440                 445 AAA GTA TGG TAA                                                     1356 Lys Val Trp 450 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 451 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 Met Lys Thr Arg Ser Glu Ile Glu Asn Arg Met Gln Asp Ile Glu Tyr 1               5                  10                  15 Ala Leu Leu Gly Lys Ala Leu Ile Phe Glu Asp Ser Thr Glu Tyr Ile 20                  25                  30 Leu Arg Gln Leu Ala Asn Tyr Glu Phe Lys Cys Ser His His Lys Asn 35                  40                  45 Ile Phe Ile Val Phe Lys His Leu Lys Asp Asn Gly Leu Pro Ile Thr 50                  55                  60 Val Asp Ser Ala Trp Glu Glu Leu Leu Arg Arg Arg Ile Lys Asp Met 65                  70                  75                  80 Asp Lys Ser Tyr Leu Gly Leu Met Leu His Asp Ala Leu Ser Asn Asp 85                  90                  95 Lys Leu Arg Ser Val Ser His Thr Val Phe Leu Asp Asp Leu Ser Val 100                 105                 110 Cys Ser Ala Glu Glu Asn Leu Ser Asn Phe Ile Phe Arg Ser Phe Asn 115                 120                 125 Glu Tyr Asn Glu Asn Pro Leu Arg Arg Ser Pro Phe Leu Leu Leu Glu 130                 135                 140 Arg Ile Lys Gly Arg Leu Asp Ser Ala Ile Ala Lys Thr Phe Ser Ile 145                 150                 155                 160 Arg Ser Ala Arg Gly Arg Ser Ile Tyr Asp Ile Phe Ser Gln Ser Glu 165                 170                 175 Ile Gly Val Leu Ala Arg Ile Lys Lys Arg Arg Val Ala Phe Ser Glu 180                 185                 190 Asn Gln Asn Ser Phe Phe Asp Gly Phe Pro Thr Gly Tyr Lys Asp Ile 195                 200                 205 Asp Asp Lys Gly Val Ile Leu Ala Lys Gly Asn Phe Val Ile Ile Ala 210                 215                 220 Ala Arg Pro Ser Ile Gly Lys Thr Ala Leu Ala Ile Asp Met Ala Ile 225                 230                 235                 240 Asn Leu Ala Val Thr Gln Gln Arg Arg Val Gly Phe Leu Ser Leu Glu 245                 250                 255 Met Ser Ala Gly Gln Ile Val Glu Arg Ile Ile Ala Asn Leu Thr Gly 260                 265                 270 Ile Ser Gly Glu Lys Leu Gln Arg Gly Asp Leu Ser Lys Glu Glu Leu 275                 280                 285 Phe Arg Val Glu Glu Ala Gly Glu Thr Val Arg Glu Ser His Phe Tyr 290                 295                 300 Ile Cys Ser Asp Ser Gln Tyr Lys Leu Asn Leu Ile Ala Asn Gln Ile 305                 310                 315                 320 Arg Leu Leu Arg Lys Glu Asp Arg Val Asp Val Ile Phe Ile Asp Tyr 325                 330                 335 Leu Gln Leu Ile Asn Ser Ser Val Gly Glu Asn Arg Gln Asn Glu Ile 340                 345                 350 Ala Asp Ile Ser Arg Thr Leu Arg Gly Leu Ala Ser Glu Leu Asn Ile 355                 360                 365 Pro Ile Val Cys Leu Ser Gln Leu Ser Arg Lys Val Glu Asp Arg Ala 370                 375                 380 Asn Lys Val Pro Met Leu Ser Asp Leu Arg Asp Ser Gly Gln Ile Glu 385                 390                 395                 400 Gln Asp Ala Asp Val Ile Leu Phe Ile Asn Arg Lys Glu Ser Ser Ser 405                 410                 415 Asn Cys Glu Ile Thr Val Gly Lys Asn Arg His Gly Ser Val Phe Ser 420                 425                 430 Ser Val Leu His Phe Asp Pro Lys Ile Ser Lys Phe Ser Ala Ile Lys 435                 440                 445 Lys Val Trp 450 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1065 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..1062 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9 ATG GTA AAT TAT AGT AAC TGC CAC TTC ATC AAA AGT CCT ATC CAC CTT       48 Met Val Asn Tyr Ser Asn Cys His Phe Ile Lys Ser Pro Ile His Leu 1               5                  10                  15 GAA AAT CAG AAG TTT GGA AGA AGA CCT GGT CAA TCT ATT AAG ATA TCT       96 Glu Asn Gln Lys Phe Gly Arg Arg Pro Gly Gln Ser Ile Lys Ile Ser 20                  25                  30 CCC AAA TTG GCT CAA AAT GGG ATG GTA GAA GTT ATA GGT CTT GAT TTT      144 Pro Lys Leu Ala Gln Asn Gly Met Val Glu Val Ile Gly Leu Asp Phe 35                  40                  45 CTT TCA TCT CAT TAC CAT GCA TTA GCA GCT ATC CAA AGA TTA CTG ACC      192 Leu Ser Ser His Tyr His Ala Leu Ala Ala Ile Gln Arg Leu Leu Thr 50                  55                  60 GCA ACG AAT TAC AAG GGG AAC ACA AAA GGG GTT GTT TTA TCC AGA GAA      240 Ala Thr Asn Tyr Lys Gly Asn Thr Lys Gly Val Val Leu Ser Arg Glu 65                  70                  75                  80 TCA AAT AGT TTT CAA TTT GAA GGA TGG ATA CCA AGA ATC CGT TTT ACA      288 Ser Asn Ser Phe Gln Phe Glu Gly Trp Ile Pro Arg Ile Arg Phe Thr 85                  90                  95 AAA ACT GAA TTC TTA GAG GCT TAT GGA GTT AAG CGG TAT AAA ACA TCC      336 Lys Thr Glu Phe Leu Glu Ala Tyr Gly Val Lys Arg Tyr Lys Thr Ser 100                 105                 110 AGA AAT AAG TAT GAG TTT AGT GGA AAA GAA GCT GAA ACT GCT TTA GAA      384 Arg Asn Lys Tyr Glu Phe Ser Gly Lys Glu Ala Glu Thr Ala Leu Glu 115                 120                 125 GCC TTA TAC CAT TTA GGA CAT CAA CCG TTT TTA ATA GTG GCA ACT AGA      432 Ala Leu Tyr His Leu Gly His Gln Pro Phe Leu Ile Val Ala Thr Arg 130                 135                 140 ACT CGA TGG ACT AAT GGA ACA CAA ATA GTA GAC CGT TAC CAA ACT CTT      480 Thr Arg Trp Thr Asn Gly Thr Gln Ile Val Asp Arg Tyr Gln Thr Leu 145                 150                 155                 160 TCT CCG ATC ATT AGG ATT TAC GAA GGA TGG GAA GGT TTA ACT GAC GAA      528 Ser Pro Ile Ile Arg Ile Tyr Glu Gly Trp Glu Gly Leu Thr Asp Glu 165                 170                 175 GAA AAT ATA GAT ATA GAC TTA ACA CCT TTT AAT TCA CCA CCT ACA CGG      576 Glu Asn Ile Asp Ile Asp Leu Thr Pro Phe Asn Ser Pro Pro Thr Arg 180                 185                 190 AAA CAT AAA GGG TTC GTT GTA GAG CCA TGT CCT ATC TTG GTA GAT CAA      624 Lys His Lys Gly Phe Val Val Glu Pro Cys Pro Ile Leu Val Asp Gln 195                 200                 205 ATA GAA TCC TAC TTT GTA ATC AAG CCT GCA AAT GTA TAC CAA GAA ATA      672 Ile Glu Ser Tyr Phe Val Ile Lys Pro Ala Asn Val Tyr Gln Glu Ile 210                 215                 220 AAA ATG CGT TTC CCA AAT GCA TCA AAG TAT GCT TAC ACA TTT ATC GAC      720 Lys Met Arg Phe Pro Asn Ala Ser Lys Tyr Ala Tyr Thr Phe Ile Asp 225                 230                 235                 240 TGG GTG ATT ACA GCA GCT GCG AAA AAG AGA CGA AAA TTA ACT AAG GAT      768 Trp Val Ile Thr Ala Ala Ala Lys Lys Arg Arg Lys Leu Thr Lys Asp 245                 250                 255 AAT TCT TGG CCA GAA AAC TTG TTA TTA AAC GTT AAC GTT AAA AGT CTT      816 Asn Ser Trp Pro Glu Asn Leu Leu Leu Asn Val Asn Val Lys Ser Leu 260                 265                 270 GCA TAT ATT TTA AGG ATG AAT CGG TAC ATC TGT ACA AGG AAC TGG AAA      864 Ala Tyr Ile Leu Arg Met Asn Arg Tyr Ile Cys Thr Arg Asn Trp Lys 275                 280                 285 AAA ATC GAG TTA GCT ATC GAT AAA TGT ATA GAA ATC GCC ATT CAG CTT      912 Lys Ile Glu Leu Ala Ile Asp Lys Cys Ile Glu Ile Ala Ile Gln Leu 290                 295                 300 GGC TGG TTA TCT AGA AGA AAA CGC ATT GAA TTT CTG GAT TCT TCT AAA      960 Gly Trp Leu Ser Arg Arg Lys Arg Ile Glu Phe Leu Asp Ser Ser Lys 305                 310                 315                 320 CTC TCT AAA AAA GAA ATT CTA TAT CTA AAT AAA GAG CGC TTT GAA GAA     1008 Leu Ser Lys Lys Glu Ile Leu Tyr Leu Asn Lys Glu Arg Phe Glu Glu 325                 330                 335 ATA ACT AAG AAA TCT AAA GAA CAA ATG GAA CAA TTA GAA CAA GAA TCT     1056 Ile Thr Lys Lys Ser Lys Glu Gln Met Glu Gln Leu Glu Gln Glu Ser 340                 345                 350 ATT AAT TAA                                                         1065 Ile Asn (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10 Met Val Asn Tyr Ser Asn Cys His Phe Ile Lys Ser Pro Ile His Leu 1               5                  10                  15 Glu Asn Gln Lys Phe Gly Arg Arg Pro Gly Gln Ser Ile Lys Ile Ser 20                  25                  30 Pro Lys Leu Ala Gln Asn Gly Met Val Glu Val Ile Gly Leu Asp Phe 35                  40                  45 Leu Ser Ser His Tyr His Ala Leu Ala Ala Ile Gln Arg Leu Leu Thr 50                  55                  60 Ala Thr Asn Tyr Lys Gly Asn Thr Lys Gly Val Val Leu Ser Arg Glu 65                  70                  75                  80 Ser Asn Ser Phe Gln Phe Glu Gly Trp Ile Pro Arg Ile Arg Phe Thr 85                  90                  95 Lys Thr Glu Phe Leu Glu Ala Tyr Gly Val Lys Arg Tyr Lys Thr Ser 100                 105                 110 Arg Asn Lys Tyr Glu Phe Ser Gly Lys Glu Ala Glu Thr Ala Leu Glu 115                 120                 125 Ala Leu Tyr His Leu Gly His Gln Pro Phe Leu Ile Val Ala Thr Arg 130                 135                 140 Thr Arg Trp Thr Asn Gly Thr Gln Ile Val Asp Arg Tyr Gln Thr Leu 145                 150                 155                 160 Ser Pro Ile Ile Arg Ile Tyr Glu Gly Trp Glu Gly Leu Thr Asp Glu 165                 170                 175 Glu Asn Ile Asp Ile Asp Leu Thr Pro Phe Asn Ser Pro Pro Thr Arg 180                 185                 190 Lys His Lys Gly Phe Val Val Glu Pro Cys Pro Ile Leu Val Asp Gln 195                 200                 205 Ile Glu Ser Tyr Phe Val Ile Lys Pro Ala Asn Val Tyr Gln Glu Ile 210                 215                 220 Lys Met Arg Phe Pro Asn Ala Ser Lys Tyr Ala Tyr Thr Phe Ile Asp 225                 230                 235                 240 Trp Val Ile Thr Ala Ala Ala Lys Lys Arg Arg Lys Leu Thr Lys Asp 245                 250                 255 Asn Ser Trp Pro Glu Asn Leu Leu Leu Asn Val Asn Val Lys Ser Leu 260                 265                 270 Ala Tyr Ile Leu Arg Met Asn Arg Tyr Ile Cys Thr Arg Asn Trp Lys 275                 280                 285 Lys Ile Glu Leu Ala Ile Asp Lys Cys Ile Glu Ile Ala Ile Gln Leu 290                 295                 300 Gly Trp Leu Ser Arg Arg Lys Arg Ile Glu Phe Leu Asp Ser Ser Lys 305                 310                 315                 320 Leu Ser Lys Lys Glu Ile Leu Tyr Leu Asn Lys Glu Arg Phe Glu Glu 325                 330                 335 Ile Thr Lys Lys Ser Lys Glu Gln Met Glu Gln Leu Glu Gln Glu Ser 340                 345                 350 Ile Asn (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 795 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..795 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11 ATG GGA AAT TCT GGT TTT TAT TTG TAT AAC ACT GAA AAC TGC GTC TTT       48 Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe 1               5                  10                  15 GCT GAT AAT ATC AAA GTT GGG CAA ATG ACA GAG CCG CTC AAG GAC CAG       96 Ala Asp Asn Ile Lys Val Gly Gln Met Thr Glu Pro Leu Lys Asp Gln 20                  25                  30 CAA ATA ATC CTT GGG ACA ACA TCA ACA CCT GTC GCA GCC AAA ATG ACA      144 Gln Ile Ile Leu Gly Thr Thr Ser Thr Pro Val Ala Ala Lys Met Thr 35                  40                  45 GCT TCT GAT GGA ATA TCT TTA ACA GTC TCC AAT AAT TCA TCA ACC AAT      192 Ala Ser Asp Gly Ile Ser Leu Thr Val Ser Asn Asn Ser Ser Thr Asn 50                  55                  60 GCT TCT ATT ACA ATT GGT TTG GAT GCG GAA AAA GCT TAC CAG CTT ATT      240 Ala Ser Ile Thr Ile Gly Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile 65                  70                  75                  80 CTA GAA AAG TTG GGA GAT CAA ATT CTT GAT GGA ATT GCT GAT ACT ATT      288 Leu Glu Lys Leu Gly Asp Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile 85                  90                  95 GTT GAT AGT ACA GTC CAA GAT ATT TTA GAC AAA ATC AAA ACA GAC CCT      336 Val Asp Ser Thr Val Gln Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro 100                 105                 110 TCT CTA GGT TTG TTG AAA GCT TTT AAC AAC TTT CCA ATC ACT AAT AAA      384 Ser Leu Gly Leu Leu Lys Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys 115                 120                 125 ATT CAA TGC AAC GGG TTA TTC ACT CCC AGT AAC ATT GAA ACT TTA TTA      432 Ile Gln Cys Asn Gly Leu Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu 130                 135                 140 GGA GGA ACT GAA ATA GGA AAA TTC ACA GTC ACA CCC AAA AGC TCT GGG      480 Gly Gly Thr Glu Ile Gly Lys Phe Thr Val Thr Pro Lys Ser Ser Gly 145                 150                 155                 160 AGC ATG TTC TTA GTC TCA GCA GAT ATT ATT GCA TCA AGA ATG GAA GGC      528 Ser Met Phe Leu Val Ser Ala Asp Ile Ile Ala Ser Arg Met Glu Gly 165                 170                 175 GGC GTT GTT CTA GCT TTG GTA CGA GAA GGT GAT TCT AAG CCC TGC GCG      576 Gly Val Val Leu Ala Leu Val Arg Glu Gly Asp Ser Lys Pro Cys Ala 180                 185                 190 ATT AGT TAT GGA TAC TCA TCA GGC ATT CCT AAT TTA TGT AGT CTA AGA      624 Ile Ser Tyr Gly Tyr Ser Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg 195                 200                 205 ACC AGT ATT ACT AAT ACA GGA TTG ACT CCG ACA ACG TAT TCA TTA CGT      672 Thr Ser Ile Thr Asn Thr Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg 210                 215                 220 GTA GGC GGT TTA GAA AGC GGT GTG GTA TGG GTT AAT GCC CTT TCT AAT      720 Val Gly Gly Leu Glu Ser Gly Val Val Trp Val Asn Ala Leu Ser Asn 225                 230                 235                 240 GGC AAT GAT ATT TTA GGA ATA ACA AAT ACT TCT AAT GTA TCT TTT TTA      768 Gly Asn Asp Ile Leu Gly Ile Thr Asn Thr Ser Asn Val Ser Phe Leu 245                 250                 255 GAG GTA ATA CCT CAA ACA AAC GCT TAA                                  795 Glu Val Ile Pro Gln Thr Asn Ala 260                 265 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 264 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12 Met Gly Asn Ser Gly Phe Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe 1               5                  10                  15 Ala Asp Asn Ile Lys Val Gly Gln Met Thr Glu Pro Leu Lys Asp Gln 20                  25                  30 Gln Ile Ile Leu Gly Thr Thr Ser Thr Pro Val Ala Ala Lys Met Thr 35                  40                  45 Ala Ser Asp Gly Ile Ser Leu Thr Val Ser Asn Asn Ser Ser Thr Asn 50                  55                  60 Ala Ser Ile Thr Ile Gly Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile 65                  70                  75                  80 Leu Glu Lys Leu Gly Asp Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile 85                  90                  95 Val Asp Ser Thr Val Gln Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro 100                 105                 110 Ser Leu Gly Leu Leu Lys Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys 115                 120                 125 Ile Gln Cys Asn Gly Leu Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu 130                 135                 140 Gly Gly Thr Glu Ile Gly Lys Phe Thr Val Thr Pro Lys Ser Ser Gly 145                 150                 155                 160 Ser Met Phe Leu Val Ser Ala Asp Ile Ile Ala Ser Arg Met Glu Gly 165                 170                 175 Gly Val Val Leu Ala Leu Val Arg Glu Gly Asp Ser Lys Pro Cys Ala 180                 185                 190 Ile Ser Tyr Gly Tyr Ser Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg 195                 200                 205 Thr Ser Ile Thr Asn Thr Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg 210                 215                 220 Val Gly Gly Leu Glu Ser Gly Val Val Trp Val Asn Ala Leu Ser Asn 225                 230                 235                 240 Gly Asn Asp Ile Leu Gly Ile Thr Asn Thr Ser Asn Val Ser Phe Leu 245                 250                 255 Glu Val Ile Pro Gln Thr Asn Ala 260 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..309 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13 ATG CAA AAT AAA AGA AAA GTG AGG GAC GAT TTT ATT AAA ATT GTT AAA       48 Met Gln Asn Lys Arg Lys Val Arg Asp Asp Phe Ile Lys Ile Val Lys 1               5                  10                  15 GAT GTG AAA AAA GAT TTC CCC GAA TTA GAC CTA AAA ATA CGA GTA AAC       96 Asp Val Lys Lys Asp Phe Pro Glu Leu Asp Leu Lys Ile Arg Val Asn 20                  25                  30 AAG GAA AAA GTA ACT TTC TTA AAT TCT CCC TTA GAA CTC TAC CAT AAA      144 Lys Glu Lys Val Thr Phe Leu Asn Ser Pro Leu Glu Leu Tyr His Lys 35                  40                  45 AGT GTC TCA CTA ATT CTA GGA CTG CTT CAA CAA ATA GAA AAC TCT TTA      192 Ser Val Ser Leu Ile Leu Gly Leu Leu Gln Gln Ile Glu Asn Ser Leu 50                  55                  60 GGA TTA TTC CCA GAC TCT CCT GTT CTT GAA AAA TTA GAG GAT AAC AGT      240 Gly Leu Phe Pro Asp Ser Pro Val Leu Glu Lys Leu Glu Asp Asn Ser 65                  70                  75                  80 TTA AAG CTA AAA AAG GCT TTG ATT ATG CTT ATC TTG TCT AGA AAA GAC      288 Leu Lys Leu Lys Lys Ala Leu Ile Met Leu Ile Leu Ser Arg Lys Asp 85                  90                  95 ATG TTT TCC AAG GCT GAA TAG                                          309 Met Phe Ser Lys Ala Glu 100 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 102 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14 Met Gln Asn Lys Arg Lys Val Arg Asp Asp Phe Ile Lys Ile Val Lys 1               5                  10                  15 Asp Val Lys Lys Asp Phe Pro Glu Leu Asp Leu Lys Ile Arg Val Asn 20                  25                  30 Lys Glu Lys Val Thr Phe Leu Asn Ser Pro Leu Glu Leu Tyr His Lys 35                  40                  45 Ser Val Ser Leu Ile Leu Gly Leu Leu Gln Gln Ile Glu Asn Ser Leu 50                  55                  60 Gly Leu Phe Pro Asp Ser Pro Val Leu Glu Lys Leu Glu Asp Asn Ser 65                  70                  75                  80 Leu Lys Leu Lys Lys Ala Leu Ile Met Leu Ile Leu Ser Arg Lys Asp 85                  90                  95 Met Phe Ser Lys Ala Glu 100 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 795 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..795 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15 TTG CAC ACC TTA GTT TTT TGC TCT TTT AAG GGA GGA ACT GGA AAA ACA       48 Leu His Thr Leu Val Phe Cys Ser Phe Lys Gly Gly Thr Gly Lys Thr 1               5                  10                  15 ACA CTT TCT CTA AAC GTG GGA TGC AAC TTG GCC CAA TTT TTA GGG AAA       96 Thr Leu Ser Leu Asn Val Gly Cys Asn Leu Ala Gln Phe Leu Gly Lys 20                  25                  30 AAA GTG TTA CTT GCT GAC CTA GAC CCG CAA TCC AAT TTA TCT TCT GGA      144 Lys Val Leu Leu Ala Asp Leu Asp Pro Gln Ser Asn Leu Ser Ser Gly 35                  40                  45 TTG GGG GCT AGT GTC AGA AGT GAC CAA AAA GGC TTG CAC GAC ATA GTA      192 Leu Gly Ala Ser Val Arg Ser Asp Gln Lys Gly Leu His Asp Ile Val 50                  55                  60 TAC ACA TCA AAC GAT TTA AAA TCA ATC ATT TGC GAA ACA AAA AAA GAT      240 Tyr Thr Ser Asn Asp Leu Lys Ser Ile Ile Cys Glu Thr Lys Lys Asp 65                  70                  75                  80 AGT GTG GAC CTA ATT CCT GCA TCA TTT TCA TCC GAA CAG TTT AGA GAA      288 Ser Val Asp Leu Ile Pro Ala Ser Phe Ser Ser Glu Gln Phe Arg Glu 85                  90                  95 TTG GAT ATT CAT AGA GGA CCT AGT AAC AAC TTA AAG TTA TTT CTG AAT      336 Leu Asp Ile His Arg Gly Pro Ser Asn Asn Leu Lys Leu Phe Leu Asn 100                 105                 110 GAG TAC TGC GCT CCT TTT TAT GAC ATC TGC ATA ATA GAC ACT CCA CCT      384 Glu Tyr Cys Ala Pro Phe Tyr Asp Ile Cys Ile Ile Asp Thr Pro Pro 115                 120                 125 AGC CTA GGA GGG TTA ACG AAA GAA GCT TTT GTT GCA GGA GAC AAA TTA      432 Ser Leu Gly Gly Leu Thr Lys Glu Ala Phe Val Ala Gly Asp Lys Leu 130                 135                 140 ATT GCT TGT TTA ACT CCA GAA CCT TTT TCT ATT CTA GGG TTA CAA AAG      480 Ile Ala Cys Leu Thr Pro Glu Pro Phe Ser Ile Leu Gly Leu Gln Lys 145                 150                 155                 160 ATA CGT GAA TTC TTA AGT TCG GTC GGA AAA CCT GAA GAA GAA CAC ATT      528 Ile Arg Glu Phe Leu Ser Ser Val Gly Lys Pro Glu Glu Glu His Ile 165                 170                 175 CTT GGA ATA GCT TTG TCT TTT TGG GAT GAT CGT AAC TCG ACT AAC CAA      576 Leu Gly Ile Ala Leu Ser Phe Trp Asp Asp Arg Asn Ser Thr Asn Gln 180                 185                 190 ATG TAT ATA GAC ATT ATC GAG TCT ATT TAC AAA AAC AAG CTT TTT TCA      624 Met Tyr Ile Asp Ile Ile Glu Ser Ile Tyr Lys Asn Lys Leu Phe Ser 195                 200                 205 ACA AAA ATT CGT CGA GAT ATT TCT CTC AGC CGT TCT CTT CTT AAA GAA      672 Thr Lys Ile Arg Arg Asp Ile Ser Leu Ser Arg Ser Leu Leu Lys Glu 210                 215                 220 GAT TCT GTA GCT AAT GTC TAT CCA AAT TCT AGG GCC GCA GAA GAT ATT      720 Asp Ser Val Ala Asn Val Tyr Pro Asn Ser Arg Ala Ala Glu Asp Ile 225                 230                 235                 240 CTG AAG TTA ACG CAT GAA ATA GCA AAT ATT TTG CAT ATC GAA TAT GAA      768 Leu Lys Leu Thr His Glu Ile Ala Asn Ile Leu His Ile Glu Tyr Glu 245                 250                 255 CGA GAT TAC TCT CAG AGG ACA ACG TGA                                  795 Arg Asp Tyr Ser Gln Arg Thr Thr 260                 265 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 264 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16 Leu His Thr Leu Val Phe Cys Ser Phe Lys Gly Gly Thr Gly Lys Thr 1               5                  10                  15 Thr Leu Ser Leu Asn Val Gly Cys Asn Leu Ala Gln Phe Leu Gly Lys 20                  25                  30 Lys Val Leu Leu Ala Asp Leu Asp Pro Gln Ser Asn Leu Ser Ser Gly 35                  40                  45 Leu Gly Ala Ser Val Arg Ser Asp Gln Lys Gly Leu His Asp Ile Val 50                  55                  60 Tyr Thr Ser Asn Asp Leu Lys Ser Ile Ile Cys Glu Thr Lys Lys Asp 65                  70                  75                  80 Ser Val Asp Leu Ile Pro Ala Ser Phe Ser Ser Glu Gln Phe Arg Glu 85                  90                  95 Leu Asp Ile His Arg Gly Pro Ser Asn Asn Leu Lys Leu Phe Leu Asn 100                 105                 110 Glu Tyr Cys Ala Pro Phe Tyr Asp Ile Cys Ile Ile Asp Thr Pro Pro 115                 120                 125 Ser Leu Gly Gly Leu Thr Lys Glu Ala Phe Val Ala Gly Asp Lys Leu 130                 135                 140 Ile Ala Cys Leu Thr Pro Glu Pro Phe Ser Ile Leu Gly Leu Gln Lys 145                 150                 155                 160 Ile Arg Glu Phe Leu Ser Ser Val Gly Lys Pro Glu Glu Glu His Ile 165                 170                 175 Leu Gly Ile Ala Leu Ser Phe Trp Asp Asp Arg Asn Ser Thr Asn Gln 180                 185                 190 Met Tyr Ile Asp Ile Ile Glu Ser Ile Tyr Lys Asn Lys Leu Phe Ser 195                 200                 205 Thr Lys Ile Arg Arg Asp Ile Ser Leu Ser Arg Ser Leu Leu Lys Glu 210                 215                 220 Asp Ser Val Ala Asn Val Tyr Pro Asn Ser Arg Ala Ala Glu Asp Ile 225                 230                 235                 240 Leu Lys Leu Thr His Glu Ile Ala Asn Ile Leu His Ile Glu Tyr Glu 245                 250                 255 Arg Asp Tyr Ser Gln Arg Thr Thr 260 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 744 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..744 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17 GTG AAC AAA CTA AAA AAA GAA GCG GAT GTC TTT TTT AAA AAA AAT CAA       48 Val Asn Lys Leu Lys Lys Glu Ala Asp Val Phe Phe Lys Lys Asn Gln 1               5                  10                  15 ACT GCC GCT TCT CTA GAT TTT AAG AAG ACG CTT CCC TCC ATT GAA CTA       96 Thr Ala Ala Ser Leu Asp Phe Lys Lys Thr Leu Pro Ser Ile Glu Leu 20                  25                  30 TTC TCA GCA ACT TTG AAT TCT GAG GAA AGT CAG AGT TTG GAT CGA TTA      144 Phe Ser Ala Thr Leu Asn Ser Glu Glu Ser Gln Ser Leu Asp Arg Leu 35                  40                  45 TTT TTA TCA GAG TCC CAA AAC TAT TCG GAT GAA GAA TTT TAT CAA GAA      192 Phe Leu Ser Glu Ser Gln Asn Tyr Ser Asp Glu Glu Phe Tyr Gln Glu 50                  55                  60 GAC ATC CTA GCG GTA AAA CTG CTT ACT GGT CAG ATA AAA TCC ATA CAG      240 Asp Ile Leu Ala Val Lys Leu Leu Thr Gly Gln Ile Lys Ser Ile Gln 65                  70                  75                  80 AAG CAA CAC GTA CTT CTT TTA GGA GAA AAA ATC TAT AAT GCT AGA AAA      288 Lys Gln His Val Leu Leu Leu Gly Glu Lys Ile Tyr Asn Ala Arg Lys 85                  90                  95 ATC CTG AGT AAG GAT CAC TTC TCC TCA ACA ACT TTT TCA TCT TGG ATA      336 Ile Leu Ser Lys Asp His Phe Ser Ser Thr Thr Phe Ser Ser Trp Ile 100                 105                 110 GAG TTA GTT TTT AGA ACT AAG TCT TCT GCT TAC AAT GCT CTT GCA TAT      384 Glu Leu Val Phe Arg Thr Lys Ser Ser Ala Tyr Asn Ala Leu Ala Tyr 115                 120                 125 TAC GAG CTT TTT ATA AAC CTC CCC AAC CAA ACT CTA CAA AAA GAG TTT      432 Tyr Glu Leu Phe Ile Asn Leu Pro Asn Gln Thr Leu Gln Lys Glu Phe 130                 135                 140 CAA TCG ATC CCC TAT AAA TCC GCA TAT ATT TTG GCC GCT AGA AAA GGC      480 Gln Ser Ile Pro Tyr Lys Ser Ala Tyr Ile Leu Ala Ala Arg Lys Gly 145                 150                 155                 160 GAT TTA AAA ACC AAG GTC GAT GTG ATA GGG AAA GTA TGT GGA ATG TCG      528 Asp Leu Lys Thr Lys Val Asp Val Ile Gly Lys Val Cys Gly Met Ser 165                 170                 175 AAC TCA TCG GCG ATA AGG GTG TTG GAT CAA TTT CTT CCT TCA TCT AGA      576 Asn Ser Ser Ala Ile Arg Val Leu Asp Gln Phe Leu Pro Ser Ser Arg 180                 185                 190 AAC AAA GAC GTT AGA GAA ACG ATA GAT AAG TCT GAT TCA GAG AAG AAT      624 Asn Lys Asp Val Arg Glu Thr Ile Asp Lys Ser Asp Ser Glu Lys Asn 195                 200                 205 CGC CAA TTA TCT GAT TTC TTA ATA GAG ATA CTT CGC ATC ATG TGT TCC      672 Arg Gln Leu Ser Asp Phe Leu Ile Glu Ile Leu Arg Ile Met Cys Ser 210                 215                 220 GGA GTT TCT TTG TCC TCC TAT AAC GAA AAT CTT CTA CAA CAG CTT TTT      720 Gly Val Ser Leu Ser Ser Tyr Asn Glu Asn Leu Leu Gln Gln Leu Phe 225                 230                 235                 240 GAA CTT TTT AAG CAA AAG AGC TGA                                      744 Glu Leu Phe Lys Gln Lys Ser 245 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18 Val Asn Lys Leu Lys Lys Glu Ala Asp Val Phe Phe Lys Lys Asn Gln 1               5                  10                  15 Thr Ala Ala Ser Leu Asp Phe Lys Lys Thr Leu Pro Ser Ile Glu Leu 20                  25                  30 Phe Ser Ala Thr Leu Asn Ser Glu Glu Ser Gln Ser Leu Asp Arg Leu 35                  40                  45 Phe Leu Ser Glu Ser Gln Asn Tyr Ser Asp Glu Glu Phe Tyr Gln Glu 50                  55                  60 Asp Ile Leu Ala Val Lys Leu Leu Thr Gly Gln Ile Lys Ser Ile Gln 65                  70                  75                  80 Lys Gln His Val Leu Leu Leu Gly Glu Lys Ile Tyr Asn Ala Arg Lys 85                  90                  95 Ile Leu Ser Lys Asp His Phe Ser Ser Thr Thr Phe Ser Ser Trp Ile 100                 105                 110 Glu Leu Val Phe Arg Thr Lys Ser Ser Ala Tyr Asn Ala Leu Ala Tyr 115                 120                 125 Tyr Glu Leu Phe Ile Asn Leu Pro Asn Gln Thr Leu Gln Lys Glu Phe 130                 135                 140 Gln Ser Ile Pro Tyr Lys Ser Ala Tyr Ile Leu Ala Ala Arg Lys Gly 145                 150                 155                 160 Asp Leu Lys Thr Lys Val Asp Val Ile Gly Lys Val Cys Gly Met Ser 165                 170                 175 Asn Ser Ser Ala Ile Arg Val Leu Asp Gln Phe Leu Pro Ser Ser Arg 180                 185                 190 Asn Lys Asp Val Arg Glu Thr Ile Asp Lys Ser Asp Ser Glu Lys Asn 195                 200                 205 Arg Gln Leu Ser Asp Phe Leu Ile Glu Ile Leu Arg Ile Met Cys Ser 210                 215                 220 Gly Val Ser Leu Ser Ser Tyr Asn Glu Asn Leu Leu Gln Gln Leu Phe 225                 230                 235                 240 Glu Leu Phe Lys Gln Lys Ser 245 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 930 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..930 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19 TTG GTT AAG AAA ATG GGC TCG ATG GCT TTC CAT AAA AGT AGA TTG TTT       48 Leu Val Lys Lys Met Gly Ser Met Ala Phe His Lys Ser Arg Leu Phe 1               5                  10                  15 TTA ACT TTT GGG GAC GCG TCG GAA ATT TGG TTA TCT ACT TTA TCT TAT       96 Leu Thr Phe Gly Asp Ala Ser Glu Ile Trp Leu Ser Thr Leu Ser Tyr 20                  25                  30 CTA ACT AGA AAA AAT TAT GCG TCT GGG ATT AAC TTT CTT GTT TCT TTA      144 Leu Thr Arg Lys Asn Tyr Ala Ser Gly Ile Asn Phe Leu Val Ser Leu 35                  40                  45 GAG ATT CTG GAT TTA TCG GAA ACC TTG ATA AAG GCT ATT TCT CTT GAC      192 Glu Ile Leu Asp Leu Ser Glu Thr Leu Ile Lys Ala Ile Ser Leu Asp 50                  55                  60 CAC AGC GAA TCT TTG TTT AAA ATC AAG TCT CTA GAT GTT TTT AAT GGA      240 His Ser Glu Ser Leu Phe Lys Ile Lys Ser Leu Asp Val Phe Asn Gly 65                  70                  75                  80 AAA GTT GTT TCA GAG GCA TCT AAA CAG GCT AGA GCG GCA TGC TAC ATA      288 Lys Val Val Ser Glu Ala Ser Lys Gln Ala Arg Ala Ala Cys Tyr Ile 85                  90                  95 TCT TTC ACA AAG TTT TTG TAT AGA TTG ACC AAG GGA TAT ATT AAA CCC      336 Ser Phe Thr Lys Phe Leu Tyr Arg Leu Thr Lys Gly Tyr Ile Lys Pro 100                 105                 110 GCT ATT CCA TTG AAA GAT TTT GGA AAC ACT ACA TTT TTT AAA ATC CGA      384 Ala Ile Pro Leu Lys Asp Phe Gly Asn Thr Thr Phe Phe Lys Ile Arg 115                 120                 125 GAC AAA ATC AAA ACA GAA TCG ATT TCT AAG CAG GAA TGG ACA GTT TTT      432 Asp Lys Ile Lys Thr Glu Ser Ile Ser Lys Gln Glu Trp Thr Val Phe 130                 135                 140 TTT GAA GCG CTC CGG ATA GTG AAT TAT AGA GAC TAT TTA ATC GGT AAA      480 Phe Glu Ala Leu Arg Ile Val Asn Tyr Arg Asp Tyr Leu Ile Gly Lys 145                 150                 155                 160 TTG ATT GTA CAA GGG ATC CGT AAG TTA GAC GAA ATT TTG TCT TTG CGC      528 Leu Ile Val Gln Gly Ile Arg Lys Leu Asp Glu Ile Leu Ser Leu Arg 165                 170                 175 ACA GAC GAT CTA TTT TTT GCA TCC AAT CAG ATT TCC TTT CGC ATT AAA      576 Thr Asp Asp Leu Phe Phe Ala Ser Asn Gln Ile Ser Phe Arg Ile Lys 180                 185                 190 AAA AGA CAG AAT AAA GAA ACC AAA ATT CTA ATC ACA TTT CCT ATC AGC      624 Lys Arg Gln Asn Lys Glu Thr Lys Ile Leu Ile Thr Phe Pro Ile Ser 195                 200                 205 TTA ATG GAA GAG TTG CAA AAA TAC ACT TGT GGG AGA AAT GGG AGA GTA      672 Leu Met Glu Glu Leu Gln Lys Tyr Thr Cys Gly Arg Asn Gly Arg Val 210                 215                 220 TTT GTT TCT AAA ATA GGG ATT CCT GTA ACA ACA AGT CAG GTT GCG CAT      720 Phe Val Ser Lys Ile Gly Ile Pro Val Thr Thr Ser Gln Val Ala His 225                 230                 235                 240 AAT TTT AGG CTT GCA GAG TTC CAT AGT GCT ATG AAA ATA AAA ATT ACT      768 Asn Phe Arg Leu Ala Glu Phe His Ser Ala Met Lys Ile Lys Ile Thr 245                 250                 255 CCC AGA GTA CTT CGT GCA AGC GCT TTG ATT CAT TTA AAG CAA ATA GGA      816 Pro Arg Val Leu Arg Ala Ser Ala Leu Ile His Leu Lys Gln Ile Gly 260                 265                 270 TTA AAA GAT GAG GAA ATC ATG CGT ATT TCC TGT CTT TCA TCG AGA CAA      864 Leu Lys Asp Glu Glu Ile Met Arg Ile Ser Cys Leu Ser Ser Arg Gln 275                 280                 285 AGT GTG TGT TCT TAT TGT TCT GGG GAA GAG GTA ATT CCT CTA GTA CAA      912 Ser Val Cys Ser Tyr Cys Ser Gly Glu Glu Val Ile Pro Leu Val Gln 290                 295                 300 ACA CCC ACA ATA TTG TGA                                              930 Thr Pro Thr Ile Leu 305                 310 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20 Leu Val Lys Lys Met Gly Ser Met Ala Phe His Lys Ser Arg Leu Phe 1               5                  10                  15 Leu Thr Phe Gly Asp Ala Ser Glu Ile Trp Leu Ser Thr Leu Ser Tyr 20                  25                  30 Leu Thr Arg Lys Asn Tyr Ala Ser Gly Ile Asn Phe Leu Val Ser Leu 35                  40                  45 Glu Ile Leu Asp Leu Ser Glu Thr Leu Ile Lys Ala Ile Ser Leu Asp 50                  55                  60 His Ser Glu Ser Leu Phe Lys Ile Lys Ser Leu Asp Val Phe Asn Gly 65                  70                  75                  80 Lys Val Val Ser Glu Ala Ser Lys Gln Ala Arg Ala Ala Cys Tyr Ile 85                  90                  95 Ser Phe Thr Lys Phe Leu Tyr Arg Leu Thr Lys Gly Tyr Ile Lys Pro 100                 105                 110 Ala Ile Pro Leu Lys Asp Phe Gly Asn Thr Thr Phe Phe Lys Ile Arg 115                 120                 125 Asp Lys Ile Lys Thr Glu Ser Ile Ser Lys Gln Glu Trp Thr Val Phe 130                 135                 140 Phe Glu Ala Leu Arg Ile Val Asn Tyr Arg Asp Tyr Leu Ile Gly Lys 145                 150                 155                 160 Leu Ile Val Gln Gly Ile Arg Lys Leu Asp Glu Ile Leu Ser Leu Arg 165                 170                 175 Thr Asp Asp Leu Phe Phe Ala Ser Asn Gln Ile Ser Phe Arg Ile Lys 180                 185                 190 Lys Arg Gln Asn Lys Glu Thr Lys Ile Leu Ile Thr Phe Pro Ile Ser 195                 200                 205 Leu Met Glu Glu Leu Gln Lys Tyr Thr Cys Gly Arg Asn Gly Arg Val 210                 215                 220 Phe Val Ser Lys Ile Gly Ile Pro Val Thr Thr Ser Gln Val Ala His 225                 230                 235                 240 Asn Phe Arg Leu Ala Glu Phe His Ser Ala Met Lys Ile Lys Ile Thr 245                 250                 255 Pro Arg Val Leu Arg Ala Ser Ala Leu Ile His Leu Lys Gln Ile Gly 260                 265                 270 Leu Lys Asp Glu Glu Ile Met Arg Ile Ser Cys Leu Ser Ser Arg Gln 275                 280                 285 Ser Val Cys Ser Tyr Cys Ser Gly Glu Glu Val Ile Pro Leu Val Gln 290                 295                 300 Thr Pro Thr Ile Leu 305 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Chlamydia trachomatis (B) STRAIN: GO/86 serotype D ( trachoma biovar ) (vii) IMMEDIATE SOURCE: (B) CLONE: pUC8-pGO plasmid, ATCC 68314 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:  1..993 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21 ATG GGT AAA GGG ATT TTA TCT TTG CAG CAA GAA ATG TCG TTA GAA TAT       48 Met Gly Lys Gly Ile Leu Ser Leu Gln Gln Glu Met Ser Leu Glu Tyr 1               5                  10                  15 AGT GAA AAG TCT TAT CAG GAA GTT TTA AAA ATT CGC CAA GAA TCC TAT       96 Ser Glu Lys Ser Tyr Gln Glu Val Leu Lys Ile Arg Gln Glu Ser Tyr 20                  25                  30 TGG AAA CGC ATG AAA AGC TTC TCC TTA TTC GAA GTT ATT ATG CAT TGG      144 Trp Lys Arg Met Lys Ser Phe Ser Leu Phe Glu Val Ile Met His Trp 35                  40                  45 ACC GCA TCA CTC AAC AAA CAT ACT TGT AGA TCA TAT CGA GGA TCT TTT      192 Thr Ala Ser Leu Asn Lys His Thr Cys Arg Ser Tyr Arg Gly Ser Phe 50                  55                  60 TTG TCT TTA GAA AAG ATT GGT CTA TTG TCC TTG GAT ATG AAT CTG CAA      240 Leu Ser Leu Glu Lys Ile Gly Leu Leu Ser Leu Asp Met Asn Leu Gln 65                  70                  75                  80 GAG TTT TCC CTT TTA AAT CAT AAT CTA ATC CTA GAT GCG ATT AAA AAA      288 Glu Phe Ser Leu Leu Asn His Asn Leu Ile Leu Asp Ala Ile Lys Lys 85                  90                  95 GTT TCC TCT GCC AAG ACT TCT TGG ACC GAA GGT ACT AAA CAA GTT CGA      336 Val Ser Ser Ala Lys Thr Ser Trp Thr Glu Gly Thr Lys Gln Val Arg 100                 105                 110 GCA GCA AGC TAT ATT TCC TTA ACA AGA TTC CTA AAC AGG ATG ACT CAA      384 Ala Ala Ser Tyr Ile Ser Leu Thr Arg Phe Leu Asn Arg Met Thr Gln 115                 120                 125 GGA ATA GTC GCT ATA GCG CAA CCT TCT AAA CAA GAA AAT AGT CGA ACA      432 Gly Ile Val Ala Ile Ala Gln Pro Ser Lys Gln Glu Asn Ser Arg Thr 130                 135                 140 TTT TTT AAA ACC AGG GAA ATA GTA AAA ACG GAT GCG ATG AAC AGT TTG      480 Phe Phe Lys Thr Arg Glu Ile Val Lys Thr Asp Ala Met Asn Ser Leu 145                 150                 155                 160 CAA ACA GCA TCC TTC CTA AAA GAG CTA AAA AAA ATC AAT GCC CGG GAT      528 Gln Thr Ala Ser Phe Leu Lys Glu Leu Lys Lys Ile Asn Ala Arg Asp 165                 170                 175 TGG TTG ATC GCC CAG ACA ATG CTC CAA GGA GGT AAA CGC TCC TCT GAA      576 Trp Leu Ile Ala Gln Thr Met Leu Gln Gly Gly Lys Arg Ser Ser Glu 180                 185                 190 GTC TTA AGC TTG GAG ATT AGT CAG ATT TGT TTC CAA CAA GCT ACC ATT      624 Val Leu Ser Leu Glu Ile Ser Gln Ile Cys Phe Gln Gln Ala Thr Ile 195                 200                 205 TCT TTC TCC CAG CTT AAG AAC CGT CAG ACA GAA AAG AGG ATT ATT ATA      672 Ser Phe Ser Gln Leu Lys Asn Arg Gln Thr Glu Lys Arg Ile Ile Ile 210                 215                 220 ACT TAT CCT CAG AAG TTT ATG CAC TTT CTA CAA GAG TAC ATC GGT CAA      720 Thr Tyr Pro Gln Lys Phe Met His Phe Leu Gln Glu Tyr Ile Gly Gln 225                 230                 235                 240 CGA AGA GGT TTT GTC TTC GTA ACT CGC TCC GGA AAA ATG GTG GGG TTA      768 Arg Arg Gly Phe Val Phe Val Thr Arg Ser Gly Lys Met Val Gly Leu 245                 250                 255 AGG CAA ATC GCC CGC ACG TTC TCT CAA GCA GGA CTA CAA GCT GCA ATC      816 Arg Gln Ile Ala Arg Thr Phe Ser Gln Ala Gly Leu Gln Ala Ala Ile 260                 265                 270 CCT TTT AAA ATA ACC CCG CAC GTG CTT CGA GCA ACC GCT GTG ACG GAG      864 Pro Phe Lys Ile Thr Pro His Val Leu Arg Ala Thr Ala Val Thr Glu 275                 280                 285 TAC AAA CGC CTA GGG TGC TCA GAC TCC GAC ATA ATG AAG GTC ACA GGA      912 Tyr Lys Arg Leu Gly Cys Ser Asp Ser Asp Ile Met Lys Val Thr Gly 290                 295                 300 CAC GCA ACC GCA AAG ATG ATA TTT GCG TAC GAT AAA TCT TCT CGA GAA      960 His Ala Thr Ala Lys Met Ile Phe Ala Tyr Asp Lys Ser Ser Arg Glu 305                 310                 315                 320 GAC AAC GCT TCA AAG AAG ATG GCT CTA ATA TAG                          993 Asp Asn Ala Ser Lys Lys Met Ala Leu Ile 325                 330 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 330 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22 Met Gly Lys Gly Ile Leu Ser Leu Gln Gln Glu Met Ser Leu Glu Tyr 1               5                  10                  15 Ser Glu Lys Ser Tyr Gln Glu Val Leu Lys Ile Arg Gln Glu Ser Tyr 20                  25                  30 Trp Lys Arg Met Lys Ser Phe Ser Leu Phe Glu Val Ile Met His Trp 35                  40                  45 Thr Ala Ser Leu Asn Lys His Thr Cys Arg Ser Tyr Arg Gly Ser Phe 50                  55                  60 Leu Ser Leu Glu Lys Ile Gly Leu Leu Ser Leu Asp Met Asn Leu Gln 65                  70                  75                  80 Glu Phe Ser Leu Leu Asn His Asn Leu Ile Leu Asp Ala Ile Lys Lys 85                  90                  95 Val Ser Ser Ala Lys Thr Ser Trp Thr Glu Gly Thr Lys Gln Val Arg 100                 105                 110 Ala Ala Ser Tyr Ile Ser Leu Thr Arg Phe Leu Asn Arg Met Thr Gln 115                 120                 125 Gly Ile Val Ala Ile Ala Gln Pro Ser Lys Gln Glu Asn Ser Arg Thr 130                 135                 140 Phe Phe Lys Thr Arg Glu Ile Val Lys Thr Asp Ala Met Asn Ser Leu 145                 150                 155                 160 Gln Thr Ala Ser Phe Leu Lys Glu Leu Lys Lys Ile Asn Ala Arg Asp 165                 170                 175 Trp Leu Ile Ala Gln Thr Met Leu Gln Gly Gly Lys Arg Ser Ser Glu 180                 185                 190 Val Leu Ser Leu Glu Ile Ser Gln Ile Cys Phe Gln Gln Ala Thr Ile 195                 200                 205 Ser Phe Ser Gln Leu Lys Asn Arg Gln Thr Glu Lys Arg Ile Ile Ile 210                 215                 220 Thr Tyr Pro Gln Lys Phe Met His Phe Leu Gln Glu Tyr Ile Gly Gln 225                 230                 235                 240 Arg Arg Gly Phe Val Phe Val Thr Arg Ser Gly Lys Met Val Gly Leu 245                 250                 255 Arg Gln Ile Ala Arg Thr Phe Ser Gln Ala Gly Leu Gln Ala Ala Ile 260                 265                 270 Pro Phe Lys Ile Thr Pro His Val Leu Arg Ala Thr Ala Val Thr Glu 275                 280                 285 Tyr Lys Arg Leu Gly Cys Ser Asp Ser Asp Ile Met Lys Val Thr Gly 290                 295                 300 His Ala Thr Ala Lys Met Ile Phe Ala Tyr Asp Lys Ser Ser Arg Glu 305                 310                 315                 320 Asp Asn Ala Ser Lys Lys Met Ala Leu Ile 325                 330 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: unknown (B) STRAIN: E. coli ATCC 68315 (vii) IMMEDIATE SOURCE: (B) CLONE: plasmid P03/GO/MC1 (ix) FEATURE: (A) NAME/KEY: Region (B) LOCATION:  1..370 (D) OTHER INFORMATION:  /label= polypeptide /note= "polypeptide is a fusion protein of the RNA-polymerase from bacteriophage MS2 and the protein encoded by the ORF3D gene of C. (ix) FEATURE: (A) NAME/KEY: Region (B) LOCATION:  107..370 (D) OTHER INFORMATION:  /label= region /note= "this portion of the fusion protein is the protein encoded by the ORF3D gene." (ix) FEATURE: (A) NAME/KEY: Region (B) LOCATION:  1..106 (D) OTHER INFORMATION:  /label= region /note= "this portion of the fusion protein is a fragment of the RNA polymerase gene from the bacteriophage MS2." (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23 Met Ser Lys Thr Thr Lys Lys Phe Asn Ser Leu Cys Ile Asp Leu Pro 1               5                   10                  15 Arg Asp Leu Ser Leu Glu Ile Tyr Gln Ser Ile Ala Ser Val Ala Thr 20                  25                  30 Gly Ser Gly Asp Pro His Ser Asp Asp Phe Thr Ala Ile Ala Tyr Leu 35                  40                  45 Arg Asp Glu Leu Leu Thr Lys His Pro Thr Leu Gly Ser Gly Asn Asp 50                  55                  60 Glu Ala Thr Arg Arg Thr Leu Ala Ile Ala Lys Leu Arg Glu Ala Asn 65                  70                  75                  80 Gly Asp Arg Gly Gln Ile Asn Arg Glu Gly Phe Leu His Asp Lys Ser 85                  90                  95 Leu Ser Trp Asp Ile Arg Ala Thr Gly Ser Met Gly Asn Ser Gly Phe 100                 105                 110 Tyr Leu Tyr Asn Thr Glu Asn Cys Val Phe Ala Asp Asn Ile Lys Val 115                 120                 125 Gly Gln Met Thr Glu Pro Leu Lys Asp Gln Gln Ile Ile Leu Gly Thr 130                 135                 140 Thr Ser Thr Pro Val Ala Ala Lys Met Thr Ala Ser Asp Gly Ile Ser 145                 150                 155                 160 Leu Thr Val Ser Asn Asn Ser Ser Thr Asn Ala Ser Ile Thr Ile Gly 165                 170                 175 Leu Asp Ala Glu Lys Ala Tyr Gln Leu Ile Leu Glu Lys Leu Gly Asp 180                 185                 190 Gln Ile Leu Asp Gly Ile Ala Asp Thr Ile Val Asp Ser Thr Val Gln 195                 200                 205 Asp Ile Leu Asp Lys Ile Lys Thr Asp Pro Ser Leu Gly Leu Leu Lys 210                 215                 220 Ala Phe Asn Asn Phe Pro Ile Thr Asn Lys Ile Gln Cys Asn Gly Leu 225                 230                 235                 240 Phe Thr Pro Ser Asn Ile Glu Thr Leu Leu Gly Gly Thr Glu Ile Gly 245                 250                 255 Lys Phe Thr Val Thr Pro Lys Ser Ser Gly Ser Met Phe Leu Val Ser 260                 265                 270 Ala Asp Ile Ile Ala Ser Arg Met Glu Gly Gly Val Val Leu Ala Leu 275                 280                 285 Val Arg Glu Gly Asp Ser Lys Pro Cys Ala Ile Ser Tyr Gly Tyr Ser 290                 295                 300 Ser Gly Ile Pro Asn Leu Cys Ser Leu Arg Thr Ser Ile Thr Asn Thr 305                 310                 315                 320 Gly Leu Thr Pro Thr Thr Tyr Ser Leu Arg Val Gly Gly Leu Glu Ser 325                 330                 335 Gly Val Val Trp Val Asn Ala Leu Ser Asn Gly Asn Asp Ile Leu Gly 340                 345                 350 Ile Thr Asn Thr Ser Asn Val Ser Phe Leu Glu Val Ile Pro Gln Thr 355                 360                 365 Asn Ala 370

## Claims

1. A pCTD plasmid isolated from Chlamydia trachomatis serotype D comprising the following nucleotide sequence: ATATTCATATTCTGTTGCCAGAAAAAACAC 50 CTTTAGGCTATATTAGAGCCATCTTCTTTG 70                  90 AAGCGTTGTCTTCTCGAGAAGATTTATCGT 110 ACGCAAATATCATCTTTGCGGTTGCGTGTC 130                 150 CTGTGACCTTCATTATGTCGGAGTCTGAGC 170 ACCCTAGGCGTTTGTACTCCGTCACAGCGG 190                 210 TTGCTCGAAGCACGTGCGGGGTTATTTTAA 230 AAGGGATTGCAGCTTGTAGTCCTGCTTGAG 250                 270 AGAACGTGCGGGCGATTTGCCTTAACCCCA 290 CCATTTTTCCGGAGCGAGTTACGAAGACAA 310                 330 AACCTCTTCGTTGACCGATGTACTCTTGTA 350 GAAAGTGCATAAACTTCTGAGGATAAGTTA 370                 390 TAATAATCCTCTTTTCTGTCTGACGGTTCT 410 TAAGCTGGGAGAAAGAAATGGTAGCTTGTT 430                 450 GGAAACAAATCTGACTAATCTCCAAGCTTA 470 AGACTTCAGAGGAGCGTTTACCTCCTTGGA 490                 510 GCATTGTCTGGGCGATCAACCAATCCCGGG 530 CATTGATTTTTTTTAGCTCTTTTAGGAAGG 550                 570 ATGCTGTTTGCAAACTGTTCATCGCATCCG 590 TTTTTACTATTTCCCTGGTTTTAAAAAATG 610                 630 TTCGACTATTTTCTTGTTTAGAAGGTTGCG 650 CTATAGCGACTATTCCTTGAGTCATCCTGT 670                 690 TTAGGAATCTTGTTAAGGAAATATAGCTTG 710 CTGCTCGAACTTGTTTAGTACCTTCGGTCC 730                 750 AAGAAGTCTTGGCAGAGGAAACTTTTTTAA 770 TCGCATCTAGGATTAGATTATGATTTAAAA 790                 810 GGGAAAACTCTTGCAGATTCATATCCAAGG 830 ACAATAGACCAATCTTTTCTAAAGACAAAA 850                 870 AAGATCCTCGATATGATCTACAAGTATGTT 890 TGTTGAGTGATGCGGTCCAATGCATAATAA 910                 930 CTTCGAATAAGGAGAAGCTTTTCATGCGTT 950 TCCAATAGGATTCTTGGCGAATTTTTAAAA 970                 990 CTTCCTGATAAGACTTTTCACTATATTCTA 1010 ACGACATTTCTTGCTGCAAAGATAAAATCC 1030                1050 CTTTACCCATGAAATCCCTCGTGATATAAC 1070 CTATCCGTAAAATGTCCTGATTAGTGAAAT 1090                1110 AATCAGGTTGTTAACAGGATAGCACGCTCG 1130 GTATTTTTTTATATAAACATGAAAACTCGT ORF1 >> 1150                1170 TCCGAAATAGAAAATCGCATGCAAGATATC 1190 GAGTATGCGTTGTTAGGTAAAGCTCTGATA 1210                1230 TTTGAAGACTCTACTGAGTATATTCTGAGG 1250 CAGCTTGCTAATTATGAGTTTAAGTGTTCT 1270                1290 CATCATAAAAACATATTCATAGTATTTAAA 1310 CACTTAAAAGACAATGGATTACCTATAACT 1330                1350 GTAGACTCGGCTTGGGAAGAGCTTTTGCGG 1370 CGTCGTATCAAAGATATGGACAAATCGTAT 1390                1410 CTCGGGTTAATGTTGCATGATGCTTTATCA 1430 AATGACAAGCTTAGATCCGTTTCTCATACG 1450                1470 GTTTTCCTCGATGATTTGAGCGTGTGTAGC 1490 GCTGAAGAAAATTTGAGTAATTTCATTTTC 1510                1530 CGCTCGTTTAATGAGTACAATGAAAATCCA 1550 TTGAGTAGATCTCCGTTTCTATTGCTTGAG 1570                1590 CGTATAAAGGGAAGGCTTGATAGTGCTATA 1610 GCAAAGACTTTTTCTATTCGCAGCGCTAGA 1630                1650 GGCCGGTCTATTTATGATATATTCTCACAG 1670 TCAGAAATTGGAGTGCTGGCTCGTATAAAA 1690                1710 AAAAGACGAGTAGCGTTCTCTGAGAATCAA 1730 AATTCTTTCTTTGATGGCTTCCCAACAGGA 1750                1770 TACAAGGATATTGATGATAAAGGAGTTATC 1790 TTAGCTAAAGGTAATTTCGTGATTATAGCA 1810                1830 GCTAGACCATCTATAGGGAAAACAGCTTTA 1850 GCTATAGACATGGCGATAAATCTTGCGGTT 1870                1890 ACTCAACAGCGTAGAGTTGGTTTCCTATCA 1910 CTAGAAATGAGCGCAGGTCAAATTGTTGAG 1930                1950 CGGATTATTGCTAATTTAACAGGAATATCT 1970 GGTGAAAAATTACAAAGAGGGGATCTCTCT 1990                2010 AAAGAAGAATTATTCCGAGTAGAAGAAGCT 2030 GGAGAAACGGTTAGAGAATCACATTTTTAT 2050                2070 ATCTGCAGTGATAGTCAGTATAAGCTTAAC 2090 TTAATCGCGAATCAGATCCGGTTGCTGAGA 2110                2130 AAAGAAGATCGAGTAGACGTAATATTTATC 2150 GATTACTTGCAGTTGATCAACTCATCGGTT 2170                2190 GGAGAAAATCGTCAAAATGAAATAGCAGAT 2210 ATATCTAGAACCTTAAGAGGTTTAGCCTCA 2230                2250 GAGCTAAACATTCCTATAGTTTGTTTATCC 2270 CAACTATCTAGAAAAGTTGAGGATAGAGCA 2290                2310 AATAAAGTTCCCATGCTTTCAGATTTGCGA 2330 GACAGCGGTCAAATAGAGCAAGACGCAGAT 2350                2370 GTGATTTTGTTTATCAATAGGAAGGAATCG 2390 TCTTCTAATTGTGAGATAACTGTTGGGAAA 2410                2430 AATAGACATGGATCGGTTTTCTCTTCGGTA 2450 TTACATTTCGATCCAAAAATTAGTAAATTC 2470                2490 TCCGCTATTAAAAAAGTATGGTAAATTATA 2510 GTAACTGCCACTTCATCAAAAGTCCTATCC ORF2>> 2530                2550 ACCTTGAAAATCAGAAGTTTGGAAGAAGAC 2570 CTGGTCAATCTATTAAGATATCTCCCAAAT 2590                2610 TGGCTCAAAATGGGATGGTAGAAGTTATAG 2630 GTCTTGATTTTCTTTCATCTCATTACCATG 2650                2670 CATTAGCAGCTATCCAAAGATTACTGACCG 2690 CAACGAATTACAAGGGGAACACAAAAGGGG 2710                2730 TTGTTTTATCCAGAGAATCAAATAGTTTTC 2750 AATTTGAAGGATGGATACCAAGAATCCGTT 2770                2790 TAACAAAAACTGAATTCTTAGAGGCTTATG 2810 GAGTTAAGCGGTATAAAACATCCAGAAATA 2830                2850 AGTATGAGTTTAGTGGAAAAGAAGCTGAAA 2870 CTGCTTTAGAAGCCTTATACCATTTAGGAC 2890                2910 ATCAACCGTTTTTAATAGTGGCAACTAGAA 2930 CTCGATGGACTAATGGAACACAAATAGTAG 2950                2970 ACCGTTACCAAACTCTTTCTCCGATCATTA 2990 GGATTTACGAAGGATGGGAAGGTTTAACTG 3010                3030 ACGAAGAAAATATAGATATAGACTTAACAC 3050 CTTTTAATTCACCACCTACACGGAAACATA 3070                3090 AAGGGTTCGTTGTAGAGCCATGTCCTATCT 3110 TGGTAGATCAAATAGAATCCTACTTTGTAA 3130                3150 TCAAGCCTGCAAATGTATACCAAGAAATAA 3170 AAATGCGTTTCCCAAATGCATCAAAGTATG 3190                3210 CTTACACATTTATCGACTGGGTGATTACAG 3230 CAGCTGCGAAAAAGAGACGAAAATTAACTA 3250                3270 AGGATAATTCTTGGCCAGAAAACTTGTTAT 3290 TAAACGTTAACGTTAAAAGTCTTGCATATA 3310                3330 TTTTAAGGATGAATCGGTACATCTGTACAA 3350 GGAACTGGAAAAAAATCGAGTTAGCTATCG 3370                3390 ATAAATGTATAGAAATCGCCATTCAGCTTG 3410 GCTGGTTATCTAGAAGAAAACGCATTGAAT 3430                3450 TTCTGGATTCTTCTAAACTCTCTAAAAAAG 3470 AAATTCTATATCTAAATAAAGAGCGCTTTG 3490                3510 AAGAAATAACTAAGAAATCTAAAGAACAAA 3530 TGGAACAATTAGAACAAGAATCTATTAATT 3550                3570 AATAGCAAGCTTGAAACTAAAAACCTAATT 3590 TATTTAAAGCTCAAAATAAAAAAGAGTTTT 3610                3630 AAAATGGGAAATTCTGGTTTTTATTTGTAT 3650 AACACTGAAAACTGCGTCTTTGCTGATAAT ORF3 >> 3670                3690 ATCAAAGTTGGGCAAATGACAGAGCCGCTC 3710 AAGGACCAGCAAATAATCCTTGGGACAACA 3730                3750 TCAACACCTGTCGCAGCCAAAATGACAGCT 3770 TCTGATGGAATATCTTTAACAGTCTCCAAT 3790                3810 AATTCATCAACCAATGCTTCTATTACAATT 3830 GGTTTGGATGCGGAAAAAGCTTACCAGCTT 3850                3870 ATTCTAGAAAAGTTGGGAGATCAAATTCTT 3890 GATGGAATTGCTGATACTATTGTTGATAGT 3910                3930 ACAGTCCAAGATATTTTAGACAAAATCAAA 3950 ACAGACCCTTCTCTAGGTTTGTTGAAAGCT 3970                3990 TTTAACAACTTTCCAATCACTAATAAAATT 4010 CAATGCAACGGGTTATTCACTCCCAGTAAC 4030                4050 ATTGAAACTTTATTAGGAGGAACTGAAATA 4070 GGAAAATTCACAGTCACACCCAAAAGCTCT 4090                4110 GGGAGCATGTTCTTAGTCTCAGCAGATATT 4130 ATTGCATCAAGAATGGAAGGCGGCGTTGTT 4150                4170 CTAGCTTTGGTACGAGAAGGTGATTCTAAG 4190 CCCTGCGCGATTAGTTATGGATACTCATCA 4210                4230 GGCATTCCTAATTTATGTAGTCTAAGAACC 4250 AGTATTACTAATACAGGATTGACTCCGACA 4270                4290 ACGTATTCATTACGTGTAGGCGGTTTAGAA 4310 AGCGGTGTGGTATGGGTTAATGCCCTTTCT 4330                4350 AATGGCAATGATATTTTAGGAATAACAAAT 4370 ACTTCTAATGTATCTTTTTTAGAGGTAATA 4390                4410 CCTCAAACAAACGCTTAAACAATTTTTATT 4430 GGATTTTTCTTATAGGTTTTATATTTAGAG 4450                4470 AAAACAGTTCGAATTACGGGGTTTGTTATG 4490 CAAAATAAAAGAAAAGTGAGGGACGATTTT ORF4 >> 4510                4530 ATTAAAATTGTTAAAGATGTGAAAAAAGAT 4550 TTCCCCGAATTAGACCTAAAAATACGAGTA 4570                4590 AACAAGGAAAAAGTAACTTTCTTAAATTCT 4610 CCCTTAGAACTCTACCATAAAAGTGTCTCA 4630                4650 CTAATTCTAGGACTGCTTCAACAAATAGAA 4670 AACTCTTTAGGATTATTCCCAGACTCTCCT 4690                4710 GTTCTTGAAAAATTAGAGGATAACAGTTTA 4730 AAGCTAAAAAAGGCTTTGATTATGCTTATC 4750                4770 TTGTCTAGAAAAGACATGTTTTCCAAGGCT 4790 GAATAGACAACTTACTCTAACGTTGGAGTT 4810                4830 GATTTGCACACCTTAGTTTTTTGCTCTTTT 4850 AAGGGAGGAACTGGAAAAACAACACTTTCT ORF5 >> 4870                4890 CTAAACGTGGGATGCAACTTGGCCCAATTT 4910 TTAGGGAAAAAAGTGTTACTTGCTGACCTA 4930                4950 GACCCGCAATCCAATTTATCTTCTGGATTG 4970 GGGGCTAGTGTCAGAAGTGACCAAAAAGGC 4990                5010 TTGCACGACATAGTATACACATCAAACGAT 5030 TTAAAATCAATCATTTGCGAAACAAAAAAA 5050                5070 GATAGTGTGGACCTAATTCCTGCATCATTT 5090 TCATCCGAACAGTTTAGAGAATTGGATATT 5110                5130 CATAGAGGACCTAGTAACAACTTAAAGTTA 5150 TTTCTGAATGAGTACTGCGCTCCTTTTTAT 5170                5190 GACATCTGCATAATAGACACTCCACCTAGC 5210 CTAGGAGGGTTAACGAAAGAAGCTTTTGTT 5230                5250 GCAGGAGACAAATTAATTGCTTGTTTAACT 5270 CCAGAACCTTTTTCTATTCTAGGGTTACAA 5290                5310 AAGATACGTGAATTCTTAAGTTCGGTCGGA 5330 AAACCTGAAGAAGAACACATTCTTGGAATA 5350                5370 GCTTTGTCTTTTTGGGATGATCGTAACTCG 5390 ACTAACCAAATGTATATAGACATTATCGAG 5410                5430 TCTATTTACAAAAACAAGCTTTTTTCAACA 5450 AAAATTCGTCGAGATATTTCTCTCAGCCGT 5470                5490 TCTCTTCTTAAAGAAGATTCTGTAGCTAAT 5510 GTCTATCCAAATTCTAGGGCCGCAGAACAT 5530                5550 ATTCTGAAGTTAACGCATGAAATAGCAAAT 5570 ATTTTGCATATCGAATATGAACGAGATTAC 5590                5610 TCTCAGAGGACAACGTGAACAAACTAAAAA 5630 AAGAAGCGGATGTCTTTTTTAAAAAAAATC ORF6 >> 5650                5670 AAACTGCCGCTTCTCTAGATTTTAAGAAGA 5690 CGCTTCCCTCCATTGAACTATTCTCAGCAA 5710                5730 CTTTGAATTCTGAGGAAAGTCAGAGTTTGG 5750 ATCGATTATTTTTATCAGAGTCCCAAAACT 5770                5790 ATTCGGATGAAGAATTTTATCAAGAAGACA 5810 TCCTAGCGGTAAAACTGCTTACTGGTCAGA 5830                5850 TAAAATCCATACAGAAGCAACACGTACTTC 5870 TTTTAGGAGAAAAAATCTATAATGCTAGAA 5890                5910 AAATCCTGAGTAAGGATCACTTCTCCTCAA 5930 CAACTTTTTCATCTTGGATAGAGTTAGTTT 5950                5970 TTAGAACTAAGTCTTCTGCTTACAATGCTC 5990 TTGCATATTACGAGCTTTTTATAAACCTCC 6010                6030 CCAACCAAACTCTACAAAAAGAGTTTCAAT 6050 CGATCCCCTATAAATCCGCATATATTTTGG 6070                6090 CCGCTAGAAAAGGCGATTTAAAAACCAAGG 6110 TCGATGTGATAGGGAAAGTATGTGGAATGT 6130                6150 CGAACTCATCGGCGATAAGGGTGTTGGATC 6170 AATTTCTTCCTTCATCTAGAAACAAAGACG 6190                6210 TTAGAGAAACGATAGATAAGTCTGATTCAG 6230 AGAAGAATCGCCAATTATCTGATTTCTTAA 6250                6270 TAGAGATACTTCGCATCATGTGTTCCGGAG 6290 TTTCTTTGTCCTCCTATAACGAAAATCTTC 6310                6330 TACAACAGCTTTTTGAACTTTTTAAGCAAA 6350 AGAGCTGATCCTCCGTCAGCTCATATATAT 6370                6390 ATATCTATTATATATATATATTTAGGGATT 6410 TGATTTCACGAGAGAGATTTGCAACTCTTG 6430                6450 GTGGTAGACTTTGCAACTCTTGGTGGTAGA 6470 CTTTGCAACTCTTGGTGGTAGACTTTGCAA 6490                6510 CTCTTGGTGGTAGACTTGGTCATAATGGAC 6530 TTTTGTTAAAAAATTTATTAAAATCTTAGA 6550                6570 GCTCCGATTTTGAATAGCTTTGGTTAAGAA 6590 AATGGGCTCGATGGCTTTCCATAAAAGTAG ORF7 >> 6610                6630 ATTGTTTTTAACTTTTGGGGACGCGTCGGA 6650 AATTTGGTTATCTACTTTATCTTATCTAAC 6670                6690 TAGAAAAAATTATGCGTCTGGGATTAACTT 6710 TCTTGTTTCTTTAGAGATTCTGGATTTATC 6730                6750 GGAAACCTTGATAAAGGCTATTTCTCTTGA 6770 CCACAGCGAATCTTTGTTTAAAATCAAGTC 6790                6810 TCTAGATGTTTTTAATGGAAAAGTTGTTTC 6830 AGAGGCATCTAAACAGGCTAGAGCGGCATG 6850                6870 CTACATATCTTTCACAAAGTTTTTGTATAG 6890 ATTGACCAAGGGATATATTAAACCCGCTAT 6910                6930 TCCATTGAAAGATTTTGGAAACACTACATT 6950 TTTTAAAATCCGAGACAAAATCAAAACAGA 6970                6990 ATCGATTTCTAAGCAGGAATGGACAGTTTT 7010 TTTTGAAGCGCTCCGGATAGTGAATTATAG 7030                7050 AGACTATTTAATCGGTAAATTGATTGTACA 7070 AGGGATCCGTAAGTTAGACGAAATTTTGTC 7090                7110 TTTGCGCACAGACGATCTATTTTTTGCATC 7130 CAATCAGATTTCCTTTCGCATTAAAAAAAG 7150                7170 ACAGAATAAAGAAACCAAAATTCTAATCAC 7190 ATTTCCTATCAGCTTAATGGAAGAGTTGCA 7210                7230 AAAATACACTTGTGGGAGAAATGGGAGAGT 7250 ATTTGTTTCTAAAATAGGGATTCCTGTAAC 7270                7290 AACAAGTCAGGTTGCGCATAATTTTAGGCT 7310 TGCAGAGTTCCATAGTGCTATGAAAATAAA 7330                7350 AATTACTCCCAGAGTACTTCGTGCAAGCGC 7370 TTTGATTCATTTAAAGCAAATAGGATTAAA 7390                7410 AGATGAGGAAATCATGCGTATTTCCTGTCT 7430 TTCATCGAGACAAAGTGTGTGTTCTTATTG 7450                7470 TTCTGGGGAAGAGGTAATTCCTCTAGTACA 7490 AACACCCACAATATTGTGATATAATTAAAA TT.

2. An isolated ORF3 gene comprising the nucleotide sequence 3604 through 4398, SEQ ID NO:11, according to claim 1.

3. An isolated ORF4 gene comprising the nucleotide sequence 4468 through 4773, SEQ ID NO:3, according to claim 1.

4. A recombinant expression vector comprising the ORF3 of claim 2.

5. A recombinant expression vector comprising the ORF4 of claim 3.

6. Escherichia coli transformed by the expression vector of claim 4.

7. Escherichia coli transformed by the expression vector of claim 5.

8. A recombinant expression vector comprising at least one gene selected from the group consisting of ORF3 comprising the nucleotide sequence 3604 through 4398, SEQ ID NO:11 and ORF4 comprising the nucleotide sequence 4468 through 4776, SEQ ID NO:13, as set forth in claim 1.

9. Escherichia coli transformed by the expression vector of claim 8.